Advertisements


FA Center: Why it matters to the stock if Facebook is a tech company or a media play

In one of these industries Facebook shares are undervalued, which influences the stock price......»»

Category: topSource: marketwatchMay 26th, 2021

Advertisers demand agencies prove their eco credentials

In this week's Insider Advertising newsletter we're covering sustainability metrics in RFPs, supply-chain issues for ad plans, and Facebook's comms. Hello and welcome back to Insider Advertising, your weekly look at the biggest stories and trends affecting Madison Avenue and beyond. I'm Lara O'Reilly, Insider's media and advertising editor. If this was forwarded to you, sign up here.As we gear up for the big holiday quarter, Facebook advertisers are already experiencing their nightmare before Christmas as Apple's recent privacy changes take effect. In a blog post Wednesday, Facebook said some advertisers' post-iOS 14 difficulties were hitting harder than they had expected. Some of those issues could be attributed to Facebook underreporting conversions on iOS devices by about 15%, the company said. Direct-to-consumer and so-called performance advertisers in particular are bracing for a bumpy Q4.Let's get you caught up on this week's other big advertising news:Marketers are pushing their ad agencies to be eco-friendlySupply-chain shortages are affecting ad plansFacebook is embarking on a more defensive comms approachIt's not easy being green Investors can make this happen, if they want to. Frank Bienewald/LightRocket via Getty Images It's been a little over five years since big brands like General Mills and HP made headlines by setting out requirements for their ad agencies to diversify their workforces.Now, an increasing number of advertisers are also asking agencies pitching for their business to lay out their sustainability commitments, the Insider correspondent Patrick Coffee reports, quoting one agency exec who said it's now part of every pitch.But while sustainability metrics are now front and center of many RFPs, I'd wager that few advertisers are at the point where they can audit compliance with the promises being made."It's an important part of any process, but many of the areas can be quite challenging on an ongoing basis," Ryan Kangisser, the managing partner of strategy at the media-advisory firm MediaSense, told me. What's more, as the coronavirus pandemic forced nearly all businesses to significantly rev up their e-commerce operations, some advertisers could do well with turning the mirror back on themselves. Global delivery volume records that were set last year are likely to be smashed once again in the holiday quarter."As e-commerce gets bigger, we all have to recognize the energy and power required to fuel all the e-commerce sites and clicks and transactions that are exponentially exploding at the moment," said Richard Robinson, a managing director of the pitch consultancy Oystercatchers.Yet, Robinson said, when brands are leaned on to ask who is ultimately responsible for sustainable e-commerce within their companies - The CMO? CDO? IT? Supply chain? - many execs still don't have a solid answer."The e-commerce kahuna is everyone's inconvenient secret at the moment," Robinson added.Hey big spenderAs e-commerce spending continues to soar through 2021 and beyond, so too is retailer spending on digital ads.Retail has long been the biggest-spending sector on digital ads in the US - which makes sense, as it's the category with the clearest visibility about whether the ads drove a sale. eMarketer; Taylor Tyson/Insider Insider Intelligence forecasts US retailer digital ad spending will blast through the $50 billion mark in 2022 - "a mark that no other industry will approach in the next couple of years," the Insider-owned research company's analysts wrote. In fact, Insider Intelligence doesn't predict any other single category will spend more than $20 billion in digital ads a year until 2023.In the meantime, retailers and e-commerce companies like Walmart, Target, and Instacart are busily building their own ad businesses and taking on the market leader Amazon by using their valuable first-party data to help advertisers target the shoppers most likely to buy their products. Insider Intelligence estimates that US retail media ad spending will grow almost 28% to reach $24 billion this year.You can't always get what you want FILE PHOTO: A General Motors assembly worker works on assembling a V6 engine, used in a variety of GM cars, trucks and crossovers, at the GM Romulus Powertrain plant in Romulus, Michigan, U.S. August 21, 2019. Rebecca Cook/File Photo Insider's senior reporter Lauren Johnson reports: Supply-chain issues are affecting ad spend, Ad Age reported, and it's not just mom and pops grappling to stock their shelves.Automakers like GM are also contending with big issues that make it hard to get their products to people, and big names are cutting advertising spend as a result, according to four agency sources who handle ad buying for the auto industry.One ad buyer said GM brands like Ford and Chevy, as well as the Dutch automaker Stellantis, cut ad spend earlier this year in response to computer-chip shortages that slashed production cycles, adding that car brands shifted their messaging from selling new vehicles to encouraging people to buy used cars at local dealerships. Representatives for Ford, Chevy, and Stellantis did not respond to requests for comment.Agency sources said that such cuts had hit mostly TV advertising and that in cases in which only some of a brand's products were unavailable, advertisers redirected digital ad spend to promote in-stock items with performance tactics like programmatic advertising that can track sales of products.Read more: KFC isn't advertising chicken tenders on TV because of supply-chain shortagesSorry seems to be the hardest word Facebook CEO Mark Zuckerberg in New York City on Friday, October 25, 2019. AP Photo/Mark Lennihan A few years ago, as sure as spring would turn to summer and summer to fall, it felt as if the latest Facebook mea culpa was only ever a few months away. (The Washington Post even made a handy timeline.) Yet while Facebook has been significantly ramping up its own ad spend of late, don't expect to see any more full-page apology ads from the social network in your favorite newspaper anytime soon.As The New York Times reported, amid the weight of negative scrutiny on the company, Facebook's communications execs are pressing on with a different strategy: No more apologies.That attack-dog approach has been in plain view following The Wall Street Journal's explosive "Facebook Files" investigative series, which uncovered a litany of serious issues on that platform that the company appears to be aware of but has failed to fully address.Facebook's vice president of global affairs, Nick Clegg, fired back with his "What the Wall Street Journal Got Wrong" blog post. Mark Zuckerberg, who personally hasn't responded to The Journal's reporting, instead wagged his finger at The Times for implying he had posted a video of himself riding an "electric surfboard" instead of a hydrofoil. Over on Twitter, a Facebook representative sought to play down The Times' reporting of "Project Amplify," the social network's initiative to show people positive stories about the company on the platform.Meanwhile, the heat on Facebook shows no sign of petering out:Another Facebook ad boycott could be around the cornerSenators said they'd investigate Facebook's internal research into Instagram's effects on the mental health of young usersOne of Wall Street's top internet analysts says Facebook and Instagram user satisfaction just dropped to all-time lowsRecommended readingWaze CMO Erin Clift has left amid leadership shake-up at the Google-owned company - InsiderRoku is rolling out a new tool to compete with Facebook and Google for the $16 billion local advertising market - InsiderAT&T CEO John Stankey says he's unhappy with the company's brand and is planning a more future-facing refresh - CNBCVideoAmp has begun testing its cross-platform TV- and video-measurement ratings alternative with five major ad holding companies - CampaignAudi is looking for a new ad agency to handle its $185 million ad business - InsiderTikTok insiders describe how parent company ByteDance's culture principles, called 'ByteStyles,' are used to reward and reprimand - InsiderSee you next week - and in the meantime please do continue sending your feedback and news tips for this newsletter to loreilly@insider.com Read the original article on Business Insider.....»»

Category: topSource: businessinsiderSep 23rd, 2021

51 gifts dog lovers and their canine companions will love

We curated 51 of our favorite gifts for dog lovers and their very good dogs, including subscription boxes, books, pj's, and custom stickers. When you buy through our links, Insider may earn an affiliate commission. Learn more. Treat your favorite chef to a dog treat maker from Dash. Target We rounded up the most unique and thoughtful gifts for dog lovers and their dogs. Show them you care with a monthly subscription box, canine home decor, and all sorts of dog books. Here are 51 useful, entertaining, and adorable gifts dogs and their humans will love. As one of the most magical and amusing creatures on earth, dogs are more than deserving of a gift every now and again. And their human guardians? Yeah, they deserve a little something too.In this list, we've curated 52 of our favorite gifts for dogs and the people who love them, including a stylish dog crate, a monthly subscription box filled with toys and treats, and custom pet stickers. Whether you want to add a little doggy decor to your home or give your favorite pet something new to play with, these gifts evoke pure joy of the canine kind.Here are 51 of the best gifts for dogs lovers and their dogs: Dog stickers that are (almost) as cute as the real thing My Sticker Face My Sticker Face Sampler Sticker Face Sheet, available on Amazon, $15.99Give the gift of sticky immortality with these customizable pet stickers. Just upload a photo of their dog and My Sticker Face will create a spot-on version made from vinyl that they can affix to anything that needs a puppy pick-me-up. A monthly box of canine surprises Bark Box Bark Box Monthly Subscription, available on Bark Box, from $23Don't bother trying to figure out exactly what the dog or dog lover in your life wants. Bark Box has done the work for you. Its monthly subscription boxes contain curated collections of toys, treats, and chews based on fun themes like summer camp, magic, and spa days. Send Bark Box as a gift or, better yet, get your own. A pack of dogs to protect their smartphone Society6 Pet Friendly Dog Pattern Phone Case, available on Society6 for both iPhone and Android, from $20.99No more scrolling their social media feeds to find cute dogs. With this smartphone case, there will already be dozens of pups at their fingertips. The pack, which includes corgis, shiba inus, and poodles, can be customized as a slim or tough case for almost any iPhone or Android model. Flannel pants for cold-weather canine snuggling L.L. Bean L.L. Bean Flannel Pants, Dog Print, available on L.L. Bean, $49.95These extra soft flannel pants will keep them warm and cozy on crisp nights. They've been designed for maximum comfort with a drawstring waist and pockets. Choose from three dog-tastic colors and prints and 13 sizes. A stress-relieving coloring book full of dogs Amazon Dog Lover: Adult Coloring Book, by Gina Trowler, available on Amazon, $6.99This charming adult coloring book is packed with 64 pages of intricately drawn black-and-white canines. Go ahead, make your great dane blue and your chihuahua pink. The book's pages are nice and thick so the colors won't bleed through. A mind-blowing book about a dog who 'talks' Amazon "How Stella Learned to Talk by Christina Hunger," available at Amazon and Target, $13.99In this fascinating book, speech-language pathologist Christina Hunger chronicles her journey teaching her dog Stella to communicate using programmable buttons. This book not only details Stella's education but breaks down Hunger's techniques so that you, too, can teach your dog to "talk." A pack of doggy chip clips Amazon Kikkerland Doggie Bag Clips, available at World Market and Amazon, from $4.99Reseal your goodie bags with an assortment of canine faces. This posse of chip clips includes a corgi, Boston terrier, bulldog, collie, dalmatian, and shiba inu, each of whom are very good dogs. The clips are made from extra-strong plastic with steel springs. A handsome dog crate to dress up your decor Amazon Diggs Revol Dog Crate, available at Diggs and Amazon, $245Down with ugly dog crates that mess up your decor! Diggs Revol isn't just stylishly designed, it folds flat in seconds and has wheels for rolling out of sight. The crate is available in three colors and comes with a puppy divider and removable, easy-to-clean floor. Fresh pet food to fill their dog's belly Just Food For Dogs Just Food for Dogs, available at Just Food for Dogs, from $5.95Just Food for Dogs uses fresh, human-grade meats and veggies to produce nutritious canine meals across six different recipes. The food is flash frozen and delivered right to their door. Read more about the best fresh dog food in our buying guide. A food puzzle to work the canine brain Nina Ottosson/Business Insider Outward Hound Nina Ottosson Dog Twister Dog Puzzle, available at Chewy and Amazon, from $12.50For smarty pants dogs that need a job to do, these food puzzles are a great way to both entertain and work the brain. Pop treats or kibble into the compartments and tap into their dog's under-utilized scavenging instincts.  A book to decode your dog's star sign Urban Outfitters "Dog Astrology" by Stella Andromeda, available at Amazon and Urban Outfitters, $14.99The astrological sun sign under which your dog was born matters, according to this playful book by Stella Andromeda. Find out what an Aries or Leo looks like among the canine set, your dog's luckiest days ,and whether you and your pup are a match written in the stars. Puppy throw pillows to dress up their decor Uncommon Goods Dog Face Pillow, available at Uncommon Goods, $25Accent their home with the friendly faces of adorable dogs. Hook-sewn by hand in the form of three different breeds — golden retriever, pug and Boston terrier — these 8-by-12-inch wool pillows will never shed, drool, or leave muddy paw prints on their sofa. A pack of dogs to keep them dry in rainy weather Reed Evins Art Reed Evins Art Umbrella, available at AKC.org and Reed Evins Art, $29.99Artist Reed Evins hand-cuts paper to create spot on collage portraits of his canine clients. He's selected a couple dozen of his favorites — droopy eared basset hounds, friendly schnauzers, and half-smiling fluffs among them — for his wind-resistant 42-inch umbrella. The water-blocking parasol has a black rubber handle with an automatic opener and comes with a dog-patterned sleeve for storage. A pair of icy bulldogs to keep their highball cool Williams Sonoma Novelty Bulldog Ice Molds, available at Williams Sonoma, $21.95Bring a little canine class to their next cocktail with Williams Sonoma's bulldog-shaped ice cubes. Made from flexible silicone, just fill the two molds with water, freeze, then run under warm water to release the hounds. The long-lasting cubes will keep their shape sip after sip. A pet camera that lets them interact with their pup Amazon Furbo Treat-Tossing Dog Camera, available at Chewy and Furbo, $161.99For those who can't stand to be away from their dog, it's the Furbo dog camera to the rescue. With the free Furbo app, they can monitor their pet from afar with a 160-degree wide-angle view, speak to them through voice chat, and toss them a treat anytime they want.  Rubber boots to wear when it's raining cats and dogs Zappos Joules Raining Cats and Dogs Rain Boot, available at Zappos and Joules, from $29.95Puddles are no match for these rubber wellies by Joules. Covered in hand-drawn pups, umbrellas, and a couple water-loving cats, the mid-calf rain boots have an adjustable side buckle, a dog bone-patterned interior, and thick grippy soles for traversing slippery sidewalks. A pair of Bernie's viral mittens to squeak and tug Bark Bernie's Paw Warmers, available at Bark Shop, $10Bernie Sanders' mittens, one of the standout stars of the 2021 presidential inauguration, are now available in doggy form. Even if they have no upcoming political events to attend, playtime with these wooly squeakers on a rope will warm up your pup with practical, no-nonsense Vermont style. All proceeds go to the state's PAWsitive Pantry, which provides families in need with food for their beloved pets. A way to finally remember if the dog actually got fed Chewy/Business Insider The Original "Did You Feed The Dog?" available at Amazon, $9.95Did you feed the dog? Can't quite remember, can you? But this simple little device, it knows. Just move the button at feeding time and they'll never get taken by their pup's second-dinner-desiring hungry eyes again. Sweet long johns for a winter full of pajama parties Chewy/Insider Toy Story "To Infinity and Beyond" Dog & Cat Jersey PJs, available at Chewy, from $13.35Dress up their pup for the world's cutest pajama party in these "Toy Story" themed PJ's from Chewy's Disney collection. The outfit comes in six sizes so that even the big boys can let their snuggle flag fly. A homemade dog treat maker Target Dash Express Dog Treat Maker, available at Amazon and Target, $29.49Treat your favorite chef to a pup-approved kitchen addition. Fill the waffle iron-like Dash with one of the recipes from the included cookbook (think: peanut butter pumpkin or cheddar bacon) for fresh bone-shaped treats hot out of the oven.  A squeezable dog water bottle for instant hydration UncommonGoods/Business Insider Dog Bowl Water Bottle, available at Chewy, $14.99Offer the dog a drink single-handedly with this unique dog water bottle. Just squeeze the leak-proof canister to fill the attached dish with water. When they've had their fill, the leftover liquid drains back into the bottle for the next time they're thirsty. A hoodie with a kangaroo pouch to keep their pup close Amazon Roodie Pet Pouch Hoodie, available at Amazon, $99Cuddly pups and the humans who love them never have to be apart with this soft cotton-polyester hoodie. The zip-up 14-inch by 9-inch by 4-inch pocket supports pets up to 15 pounds and comes in six colors. A ball launcher for supercharged games of fetch Amazon/Insider Chuckit! Launcher, available at Chewy and Amazon, $4.71It's almost impossible to tire out a fetch-loving high-energy dog before tiring out your throwing arm, that is, unless you have the Chuckit! With just a flick of the wrist, this simple plastic launcher sends the ball farther than puny human muscles alone and is guaranteed not to quit halfway through the game. A matching bandana and face mask for twinning with their dog Goodboy Goodboy x Sock Fancy Bandana & Mask, available at Goodboy, $24Social distance in style with this dog bandana and face mask duo. The pair comes in four machine-washable custom cotton prints and the triple-layer mask has adjustable ear loops and a 3D chin design. A pair of fur-sonalized silver cufflinks UncommonGoods Custom Pet Portrait Cufflinks, available at Uncommon Goods, $260They'll wear their heart on their sleeve with these pet portrait cufflinks by designer Erin Harris. The engraved sterling silver accessories arrive with a bonus gift, too: a rubber stamp of their dog to use on anything that needs a bit of puppy love. A collar for tracking their dog's location and activity Chewy Fi Series 2 GPS Tracker Smart Dog Collar, available at Chewy, $149Like a FitBit for the canine set, this smart collar will not only help them keep tabs on their dog's daily activity (and compare it to other pups in the neighborhood) but on their location, too. Using GPS tracking technology, this little device sends alerts anytime a door-dashing escape artist is on the move. Their dog in sock form Chewy Tribe Socks Personalized Pet Face Socks, available at Tribe Socks, $24Wrap their barking dogs in puppy love with a pair of customizable socks. Chewy will pattern a pair with the face of their furry friend using just a photo. Choose from four styles: holiday, tie-dye, mosaic, and dog paw. The one toy every dog needs Kong/Business Insider Kong Classic, available at Chewy, from $7.99Whether they've got a puppy who's learning the ropes, an adult dog who loves a good game, or a slow-moving senior, the Kong Classic is a must for busting boredom and tapping into a dog's scavenging instincts. Just pack the heavy-duty rubber cone with treats, kibble, or peanut butter (among other things) and that big, slobbery tongue will do the rest. An elevated bed to keep their dog cool in the heat Chewy K&H Products Elevated Dog Bed, available at Chewy, from $40.99Make the dog days of summer a little more bearable for their pooch with this elevated cot. Made from waterproof nylon with a mesh center, the raised design promotes airflow that helps keep dogs from overheating when the mercury rises. A sleepy puppy hamper to snuggle their dirty clothes Amazon/Business Insider Fankang Dog Hamper, available at Amazon, $10.99Add a dose of cute to laundry day with this dog hamper. The folding, pop-up basket made of waterproof-coated cotton fabric with handles for ears also makes a great storage bin for toys, whether they belong to a dog or to a dog-loving kid. A bucket list activity journal for dog lovers and their canine compatriots Amazon/Business Insider "Chew This Journal" by Sassafras Lowrey, available at Amazon and Barnes & Noble, from $13.99Drawing from 20 years of experience, certified trick dog trainer and doggy writer extraordinaire Sassafras Lowrey's "Chew This Journal" is jam-packed with fun activities for both dog and human. From urban agility and tips on setting training goals to dog-friendly crafts like DIY treat puzzles and tug-toy-making, this book will encourage them to never stop seeking out new adventures. A bag of delicious treats with a minimal carbon paw print Chewy/Business Insider Jiminy's Chewy Cricket Treats, available at Chewy and Amazon, from $9.95Maybe dog treats can't save the world, but Jiminy's cricket treats are doing their part to help our pups live more sustainably. These tasty morsels are hypoallergenic, probiotic, and produce 740% fewer greenhouse gasses than those made with beef. Choose from two chewy flavors, sweet potato and peas or pumpkin and carrot, or crunchy peanut butter and blueberry cookies. A people-approved mattress made just for dogs Casper/Instagram Dog Mattress, available at Casper, from $129Mattress company Casper takes dog bed comfort next level with a memory foam model that rivals those they make for humans. The result of 110 prototypes and 460 hours of lab testing, with this dog bed they'll rest assured their best friend will be getting a good night's sleep.  A dog-splattered dish towel that really sees them Paper Source/Business Insider Dogs Tea Towel, available at Blue Q, $12.99Anyone who's ever loved a dog knows the best people are the fluffy, four-legged kind. And this canine-covered tea towel, it's not afraid to speak the truth. Short-haired, curly-haired, little-legged, and big, they'll be ready to go anytime a dish needs drying.  A custom cookie cutter for making edible puppy portraits SusancraftsShop/Etsy Custom Pet Portrait Cookie Cutter, available at Etsy, from $30If they think their dog couldn't get any sweeter, Bakers Street Cutters begs to differ. Send in a photo and they'll 3D print a custom cookie cutter that makes a perfect impression of their pup every time. A blueprint of their favorite breed's best qualities Etsy Dog Blueprints, available at Etsy, $29.99These vintage-inspired blueprints by canine architects Wet Nose Wiggly Butts break down the characteristics that make different dog breeds unique. Each 16-by-20-inch print features picture-perfect representations of 54 of the most popular pups, from chihuahuas to Newfoundlands. Choose to add their dog's name to the drawing for a personalized touch. A yoga mat covered in stretching Frenchies Society6 Huebucket Frenchie Yoga Mat, available at Society6, $33Flexible Frenchies show off their yoga skills on this adorable yoga mat. Their favorite pose? Downward-facing dog, of course. An honest mug that works as hard as they do Etsy/Business Insider "I work hard so my dog can have a better life" mug, available at Etsy, from $14.45For anyone with lingering doubts about where a dog parent's disposable income goes, this fully customizable mug spells it out in plain English. No one needs to know that dogs work hard to keep us happy, too. Sloppy kisses and dog hair may not pay the bills but they're worth their weight in gold. A lickable mat for anxiety-reducing enrichment Hyper Pet/Insider Hyper Pet IQ Treat Mat 2-pack, available at Chewy and Amazon, $14.95Licking a flavor-filled surface doesn't just release calming endorphins in a dog's brain, it gives them something to focus on when their stress levels become elevated. Spread these dishwasher-safe rubber mats with a soft-and-creamy favorite like yogurt, pumpkin, or peanut butter for a snack that will last and last. Read our full review of the Hyper Pet IQ Treat Mats. A flirt pole for tough tugging thrills Ren Volpe/Business Insider Outward Hound Tail Teaser, available at Chewy and Amazon, $16.99Release the hounds — or their energy, at least — with a doggy flirt pole. Like a beefed-up cat wand, this canine version features a squeaking, rattling faux-fur tail strung with durable nylon cord to a long, flexible pole that can be swung around for a high-speed game of chase, jump, and tug.  A collar from a company that supports and empowers Kenyan artisans Ubuntu Life Triangle Dog Collar in lavender, pink, or cobalt blue, available at Ubuntu Life, $59Yes, this fashion-forward collar produced by Maasai women in Kenya's Ngong Hills looks good, but it does good, too. Ubuntu Life is a public benefit corporation that provides sustainable employment, education, and healthcare to its workers and artisans, as well as pediatric health and special needs education throughout the region. The carefully crafted, highly resilient collar is made from leather and glass beads and comes in three sizes and four colors. A playful seat cover to brighten up the car Chewy Molly Mutt Multi-Use Seat Cover, available at Chewy and Amazon, $59Protect their car from doggy dirt and slobber with a fun toile-like dog patterned seat cover. The versatile cotton canvas can be draped over the back seat (the design features seatbelt slots, nonskid backing and adjustable headrest straps), converted into a car hammock or layered over the cargo hold. A 2-in-1 tool to make bath time less stressful Chewy/Insider Aquapaw Pet Bathing Tool, available at Chewy and Amazon, $24.95Speed up bath time with this flexible water sprayer and massaging scrubber. The tool slips over the palm, leaving their fingers free to reassure their pup or toggle the built-in on-and-off switch. A smiling bouncy ball that doubles as a puzzle toy Chewy/Insider Rogz Grinz Treat Ball, available at Amazon, from $10.95This durable ball will put a maniacal grin on their pup's face. Bounce it on the ground, float it in the water, or fill it with treats or kibble for extended play. It comes in four bright, impossible to lose colors and three sizes. A vet play set to inspire young animal lovers Amazon Melissa & Doug Pet Vet Play Set, available at Amazon, $24.43Encourage the little animal lover in your life with a play set that lets them practice pet care and the empathy and compassion that comes along with it. This kit comes packed with all they'll need to make a house call, including a stethoscope, syringe, bandages, and a cone of shame, as well as two plush pets to practice on. A gallery-worthy portrait of their beloved pet West & Willow Custom Pet Portrait, available at West & Willow, from $65Immortalize their fur baby with a custom portrait they'll cherish for years to come. Choose from a handful of backgrounds and hardwood frames. Each gallery-quality image can include up to three pets. A cashmere turtleneck for cold weather walks The Barkers Fido Turtleneck, available at The Barkers, $89The beatnik vibes are on point with this cable-knit turtleneck from The Barkers. Made from 100% cashmere, this luxurious dog sweater will have them wishing for a human-sized version all their own. A pack of dogs who love a relaxing bath tandemsy/Society 6 Dog Shower Curtain, available at Society 6, $45.49Add a touch of canine couture to their bathroom with a dog print shower curtain patterned in artistically arranged pups. The polyester 71-by-74-inch curtain comes with 12 buttonholes for easy hanging. A combination backpack and airline approved carrier for versatile adventures Petco Sherpa 2-in-1 Travel Backpack, available at Petco, $52.99Up in the air or on the trail, their dog can go anywhere they do with Sherpa's 2-in-1 travel backpack. The cozy, well-ventilated go bag has removable straps that convert it from a backpack to a traditional airline approved pet carrier that fits under the seat in the cabin. A boho bed cover to rest their weary head The Foggy Dog Amani Sea Dog Bed, available at The Foggy Dog, from $65Upgrade their naps with a mud-cloth inspired, upholstery-grade cotton bed cover. The durable, zip-up doggy duvet can be fitted over an old bed, pillow, or pile of blankets, or you can purchase a new memory foam or "Sustainafill" insert for maximum comfort. It's machine washable and sold in three colors. A book for youngsters about a dog's most valuable superpower Amazon/Business Insider "What the Dog Knows Young Readers Edition" by Cat Warren, available at Amazon and Barnes & Noble, $7.99In the young readers edition of the New York Times bestseller "What the Dog Knows," Cat Warren uncovers the science behind the amazing canine nose. If you know a kiddo with a love of dogs, this book full of photos and illustrations is sure to intrigue, surprise, and delight. Read the original article on Business Insider.....»»

Category: topSource: businessinsiderSep 21st, 2021

Payment Revolution Continues to Boost Fintech: 5 Top Picks

Rapid adoption of digital payment and online banking is boosting the fintech space and calls for investing in MercadoLibre (MELI), Visa (V), Green Dot (GDOT), Global Payments (GPN), & LendingClub (LC) The coronavirus pandemic has reshaped the fintech space, boosting digital payment and online banking across the globe. The mass population has shifted from currency notes to tap-and-pay modes, as it lowered the risk of virus transmission. From e-commerce giants to minuscule brick and mortar retailers, the need for digital payment systems is growing constantly.Digital payments have been popularized as they allow consumers to quickly, conveniently, and inexpensively send money across the globe. Additionally, areas like business-to-business payments are bringing a revolution in payment methods. Companies like AvidXChange, MineralTree, and Billtrust target invoicing and payment processing. With the help of artificial intelligence (AI), fintech companies are helping even small-scale businesses to automate and remove labor-intensive paperwork. Rather than having employees manually process every invoice/payment, AI-based automated systems are handling these functions or routines all at once, and letting the staff take care of problematic transactions and concentrate on customer-centric approaches.Trends like cryptocurrency, online and mobile banking, online and peer-to-peer lending, person-to-person payments, financial software, and services will continue to boost the fintech space, even if the economy goes back to the pre-pandemic stage. And, why not? Mobile applications such as Amazon Pay, Square, and PayPal are replacing bank cards (both credit and debit cards), while cryptocurrencies are gaining importance and may become a usual means of payment like fiat money.Additionally, technological advancements have mitigated issues like cybersecurity with respect to digital financial transactions. While AI helps in detecting fraud, clearing and settlement, digital identity, and payments, cloud computing aids in removing paper-based systems in business-to-business payments.The fintech space is also getting a boost from new startups, IPOs, and mergers. Robinhood, which went public this July, had gained more than 50% within a month. Another fintech startup, Toast, an all-in-one point-of-sale and restaurant management & payment platform for the food service and hospitality space, seeks to raise $18 billion in IPO by selling 21.7 million shares priced between $34 and $36 each.Earlier in September, fintech startup Pagaya Technologies Ltd., announced that is going public through a merger with a special-purpose acquisition company, EJF Acquisition Corp., with the deal valued at about $9 billion.Overall, fintech companies are evolving constantly, from compromising transaction fees to draw in merchants to payment ecosystems, to building out easy two-sided platforms for merchants and consumers. Per a Market Data Forecast report, fintech services have a global adoption rate of 25%, which includes banking and payments, financial management, financing and insurance. In fact, the global fintech market is expected to reach $324 billion by 2026, at a CAGR of 23.4% between 2021 and 2026.5 Top Fintech PicksThe explosion of fintech is not surprising, all the more, the tech-savvy millennial is driving the massive change in banking and financials. They are not only adopting mobile banking and tap-and-pay services but also forcing brick-and-mortar banks to become tech-enabled to make transactions easier. Given the change in trends and fintech’s positive outlook, we have shortlisted five stocks that can make the most.MercadoLibre, Inc. MELI operates online commerce platforms. Its Mercado Pago payments platform also processes payments outside MercadoLibre’s e-commerce platform.The company's expected earnings growth rate for the current year is more than 100% compared with the Zacks Internet - Commerce industry’s projected earnings growth of 13.5%. The Zacks Consensus Estimate for the company’s current-year earnings has been revised more than 100% upward over the past 60 days.MercadoLibre currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Visa Inc. V operates as a payment technology company. It offers VisaNet, a transaction processing network that enables authorization, clearing, and settlement of payment transactions. In August, the company purchased $150,000 worth CryptoPunk 7610, non-fungible token (NFT) commerce from Larva Labs. Visa believes that these NFTs will play an important role in the future of retail, social media, entertainment, and commerce.The company that belongs to the Zacks Financial Transaction Services industry has a projected earnings growth of 15.5% for the current year. The Zacks Consensus Estimate for the company’s current-year earnings has been revised 3.6% upward over the past 60 days. Visa currently holds a Zacks Rank #2 (Buy). Green Dot Corporation GDOT operates as a financial technology and bank holding company. It offers a banking-as-a-service (BaaS) platform used by giants like Apple, Uber, and Stash. This Zacks Rank #2 company that belongs to the Zacks Financial Transaction Services industry has a projected earnings growth of 6.2% for the current year. The Zacks Consensus Estimate for the company’s current-year earnings has been revised 5.2% upward over the past 60 days.Global Payments Inc. GPN provides payment technology and software solutions for card, electronic, check, and digital-based payments.  The company's expected earnings growth rate for the current year is nearly 28% compared with the Zacks Financial Transaction Services industry’s projected earnings growth of 19.3%. The Zacks Consensus Estimate for this Zacks Rank #2 company’s current-year earnings has been revised nearly 2% upward over the past 60 days.LendingClub Corporation LC provides a range of financial products and services through a technology-driven platform. The company boasts more than 3.5 million members, deep data capabilities, and an efficient operating platform. In the second quarter of 2021, LendingClub’s revenues more than tripled to $204.38 million.The company's expected earnings growth rate for the current year is 92.2% compared with the Zacks Financial - Miscellaneous Services industry’s projected earnings growth of 20.5%. The Zacks Consensus Estimate for the company’s current-year earnings has been revised 1.8% upward over the past 60 days. LendingClub currently carries a Zacks Rank #2. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Visa Inc. (V): Free Stock Analysis Report Global Payments Inc. (GPN): Free Stock Analysis Report Green Dot Corporation (GDOT): Free Stock Analysis Report MercadoLibre, Inc. (MELI): Free Stock Analysis Report LendingClub Corporation (LC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksSep 21st, 2021

NASDAQ Plunges 3% as 10-Year Yield Crosses 1.7%

NASDAQ Plunges 3% as 10-Year Yield Crosses 1.7% Just when you thought the Fed had soothed the jittery mind of investors in its recent statement, bond yields surged again on Thursday and kicked the legs out from under the tech space. The NASDAQ plunged 3.02% (or nearly 410 points) to 13,116.17, which snapped a three-day win streak and puts it down 1.6% for the week heading into Friday. The last time this index dipped by more than 3% was February 25 when it plunged over 3.5%. All of the FAANGs were sharply lower (as you’d expect), especially declines of more than 3% each for Netflix (NFLX), Amazon (AMZN) and Apple (AAPL). Furthermore, Tesla (TSLA) dipped 6.9% and Microsoft (MSFT) slumped nearly 2.7%. The S&P was off 1.48% today to 3915.46. The Dow reached an intraday high earlier, but reversed course and ultimately ended lower by 0.46% (or around 150 points) to 32,862.30. Both of these indices are coming down from record highs set on Wednesday. The S&P is now in the red by 0.7% for this week heading into Friday, but the Dow is up 0.3% over the four days. If the market flipped out when the 10-year Treasury yield moved above 1.6% earlier this year, then it’s certainly going to react when it soars to 1.75% like it did today. It pulled back from that high, but still finished over 1.7% on Thursday. The move comes a day after a close-to-perfect Fed statement, in which the Committee sharply raised its growth forecast for 2021 but said there’ll probably be no rate hikes through 2023. And they’re going to give inflation more latitude before making any change to policy. Adding to today’s pressure was a disappointing jobless claims report, which rose to 770,000 last week. The result wasn’t even in the same neighborhood as expectations at only 700K. It was also more than the previous result of 725K, which was revised up from 712K. Today's Portfolio Highlights: Headline Trader: These days, everybody is spending on data center expansion to capitalize on the “4th Industrial Revolution”. And they’re spending BIG money! For example, a large portion of Alphabet’s (GOOG) $7 billion capital expenditures this year will be going to data centers, which is fabulous news for Equinix (EQIX). It’s the world’s largest data center REIT and has the highest-quality portfolio of network-dense assets. Best of all, approximately 45% of Google Cloud’s onramps are already at one of EQIX’s global locations. The stock pulled back recently on a lower-than-expected forward guidance, so Dan sees an amazing opportunity to pick up a name that’s in one of the market’s sweetest spots. This addition is a play on the economic rebound and the necessity to leverage digital technology as the digital office space continues to grow. Read the full write-up for a lot more on this new addition.   Technology Innovators: A dip in shares of Amkor Technology (AMKR) is giving Brian an opportunity to pick up this chip name at a great price. This Zacks Rank #1 (Strong Buy) is a leading provider of semiconductor packaging and test services. The company has beaten the Zacks Consensus Estimate in each of the last four quarters with an impressive average surprise of 359% over that time. Furthermore, the editor considers AMKR to be “a winner based on valuation alone” given its 13x forward PE and price to book of 2.5x. The portfolio also sold the underperforming C3.ai (AI) position. The full write-up has more on today’s moves. Counterstrike: The NASDAQ is certainly “having some issues” today, which prompted Jeremy to put on a hedge and reduce some risk on Thursday. He added a 5% allocation in ProShares UltraPro Short QQQ (SQQQ), while selling Anaplan (PLAN) and Zillow Group (ZG) for losses. Read the full write-up for more on today’s moves, including why the editor thinks a 200-day test might be in the works for the NASDAQ. In other news, this portfolio had a top performer today as its short position in The RealReal (REAL) advanced approximately 6.5%. TAZR Trader: The NASDAQ is struggling with resistance, so Kevin decided to take some big profits off the table in three positions. He sold Novavax (NVAX) for a 37.5% return in just two weeks and Magnite (MGNI) for 24.5% in about the same amount of time. The editor also cut half of Square (SQ) for 17.4% in about four months. Learn more about these moves in the full write-up. Commodity Innovators: Tight supply issues for palladium has Jeremy thinking that this commodity will continue moving higher. Therefore, he added Aberdeen Standard Physical Palladium Shares ETF (PALL) on Thursday, while also selling UFP Industries (UFPI) for a nice 25.9% return. The editor sees PALL as a long-term holding. Read the full write-up for more. Zacks Short Sell List: This portfolio was made for difficult days like this, so it’s no surprise that it had four of the top five winners in a session when the S&P plunged more than 1.4%. Those strong performances on Thursday came from short positions in Ceridian HCM Holding (CDAY, +7.1%), Twitter (TWTR, +4.8%), Teradata (TDC, +4.7%) and Shopify (SHOP, +4.4%). Learn more about this emotion-free portfolio that takes advantage of falling and volatile markets by reading the Short Sell List Trader Guide. All the Best, Jim Giaquinto Recommendations from Zacks' Private Portfolios: Believe it or not, this article is not available on the Zacks.com website. The commentary is a partial overview of the daily activity from Zacks' private recommendation services. If you would like to follow our Buy and Sell signals in real time, we've made a special arrangement for readers of this website. Starting today you can see all the recommendations from all of Zacks' portfolios absolutely free for 7 days. Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises (which we've predicted with an astonishing 80%+ accuracy). Click here to "test drive" Zacks Ultimate for FREE >>  Zacks Investment Research.....»»

Category: topSource: zacksSep 21st, 2021

Stocks Bounce Back and Snap Three-Day Skid

Stocks Bounce Back and Snap Three-Day Skid Investors calmed down from the recent inflation-induced frenzy on Thursday, allowing the major indices to recover a significant amount of yesterday’s selloff and snap a three-day losing streak. However, stocks are still down for the week heading into Friday. The Dow jumped 1.29% (or about 433 points) today to 34,021.45, while the S&P rose 1.22% to 4112.50. These indices each recovered more than half of their Wednesday drops. The NASDAQ didn’t come close to halving its recent deficit, but did manage to climb 0.72% (or about 93 points) to 13,124.99. The market had a really bad reaction to yesterday’s CPI report, which stated that consumer prices jumped well past expectations in April by soaring 4.2% year over year. Such a spike in inflation is one of the bigger concerns of investors right now, which sent each of the major indices careening lower by 2% or more on Wednesday. They obviously simmered down today, even though the Producer Price Index jumped more than 6% last month. How about some good economic data! Jobless claims last week hit another new pandemic low of 473,000. The result was better than expectations closer to 500K and the previous week’s 498K (or 507K after being upwardly advised). That’s a much better result than last Friday’s Government Employment Situation, which fell short of expectations by around 700K. There were a couple big earnings reports on Wednesday, including e-commerce giant Alibaba (BABA). Sales jumped year over year, but earnings fell short of the Zacks Consensus Estimate by about 15%. That’s more than enough for this market to turn sour on a company. Shares of BABA were down nearly 6.3% in the session, but are up about 0.5% afterhours, as of this writing. Meanwhile, Disney (DIS) reported after the bell and beat the Zacks Consensus Estimate by more than 170%. However, revenue and Disney+ subscriber counts were lighter than expected. Once again, that’s not good enough this season. Shares of DIS were up 0.3% during the session before its report, but are off more than 4% afterhours, as of this writing. The major indices were mixed last week with the Dow and S&P both higher, while the NASDAQ was solidly lower. This time, they’re all solidly lower for the week heading into Friday. Let’s see what happens tomorrow... Today's Portfolio Highlights: Blockchain Innovators: The safe transport of COVID-19 vaccines is of paramount importance to the economy’s re-opening, so Dave added a stock on Thursday that’s part of this crucial pipeline. CalAmp (CAMP) is a leading provider of wireless communications products that enable anytime/anywhere access to critical information, data and entertainment content. The company has a smart tracking software solution called SC1302, which can monitor in temperatures as low as -20 degrees Celsius and link up with the company’s software. Needless to say, blockchain technology is a big help in making this happen. EPS growth for CAMP is forecasted at 70% this year and more than 35% for next, while its valuation is far below the industry average. The editor added CAMP on Thursday, while also getting out of the underperforming Rekor (REKR) and Amtech (ASYS) positions. Read the full write-up for more on today’s action.   Counterstrike: Stocks have dipped enough that Jeremy is starting to “nibble” a bit, but he’s keeping the positions small since the market could have further to fall. On Thursday, he added a 4% position in social media pioneer Facebook (FB), which has sold off recently following a fantastic quarter with a 40% positive surprise. The editor also added a further 6% to Boyd Gaming (BYD) before its next leg higher and added 3% more to Invesco Solar ETF (TAN) as the group is “overdone”. Read the complete commentary for more on today’s moves. Headline Trader: After the surge in yesterday’s CPI report, Dan decided to add an “inflation play” on Thursday. He picked up Teledyne Technologies (TDY), which is a high growth industrial business that's categorized under aerospace & defense. However, the editor notes that its end markets are much broader than that and include several industries at the forefront of the “4th Industrial Revolution”. The companies in these spaces rely heavily on TDY’s cutting-edge tech-driven products, so it will be able to easily pass its price increases onto these end markets with little to no margin deterioration. TDY just released a “blowout” first-quarter report and is on the verge of closing its acquisition of FLIR Systems. Dan thinks the stock is currently under-the-radar and is poised to head towards his $500 price target, which would mark a 20% upside. Read the full write-up for a lot more on TDY.    Commodity Innovators: With the market showing strength for the first time this week, Jeremy thought this was a good time to cash in a few names that aren’t coming along for the ride. A lull in the grains bull market is taking a toll on fertilizer names, so the editor sold Mosaic (MOS) for a nice 30% return in a little over three months and Nutrien (NTR) for 8.3% in less than a month. Meanwhile, Cameco Corp. (CCJ) faltered after pushing through $20 and could be about to dip further. Jeremy sold this uranium producer on Thursday while he could still secure a 10.5% profit in just about three months. See the full write up for more. All the Best, Jim Giaquinto Recommendations from Zacks' Private Portfolios: Believe it or not, this article is not available on the Zacks.com website. The commentary is a partial overview of the daily activity from Zacks' private recommendation services. If you would like to follow our Buy and Sell signals in real time, we've made a special arrangement for readers of this website. Starting today you can see all the recommendations from all of Zacks' portfolios absolutely free for 7 days. Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises (which we've predicted with an astonishing 80%+ accuracy). Click here to "test drive" Zacks Ultimate for FREE >>  Zacks Investment Research.....»»

Category: topSource: zacksSep 21st, 2021

S&P, NASDAQ Keep Setting Records to Begin Big Week of Data

S&P, NASDAQ Keep Setting Records to Begin Big Week of Data Another strong day for tech kept two of the major indices on their record-breaking pace to start this last week of the second quarter. But the big news comes in the next few days, as a week full of economic data concludes on Friday with the all-important Government Employment Situation report. The NASDAQ jumped 0.98% (or about 140 points) on Monday to 14,500.51, which marks its fourth record close in the past 5 sessions. The S&P was up 0.23% to 4290.61 for a third straight new high. The Dow was off 0.44% (or about 150 points) to 34,283.27. Stocks really had the wind at their backs coming into the session after such a strong performance last week. The Dow ended Friday higher by 3.4% for the previous five days, while the S&P was up 2.7% and the NASDAQ advanced 2.4%. The market sidestepped another soaring PCE result on hopes that these increases are transitory. It also benefited from an infrastructure agreement and a successful round of stress tests for the banks. On Monday, though, the big deal was good old Facebook (FB). The social media pioneer advanced practically 4.2% after a federal judge threw out the FTC’s antitrust complaint against the company, though it could be filed again. Another antitrust lawsuit from dozens of states was also dismissed. As a result, FB’s market cap surpassed $1 Trillion for the first time. Meanwhile, Apple (AAPL), Amazon (AMZN), Netflix (NFLX) and Microsoft (MSFT) were all on point as well with gains of more than 1% each. The upcoming jobs report will keep investors nervous all week, especially since the last one was pretty much perfect. But that result is coming on Friday, and there’s plenty of other data coming out before then. We’ve got the consumer confidence index tomorrow and the ADP employment on Wednesday. Per usual, jobless claims comes out on Thursday, but so does ISM manufacturing and construction spending. This week of data and the upcoming earnings season are two big factors that will help determine the market’s direction moving forward. Today's Portfolio Highlights: Headline Trader: Despite marginally missing earnings expectations, FedEx (FDX) had solid underlying fundamentals in its recent quarterly report. This express delivery staple obviously has a big part to play in the “new normal”. Analysts believe FDX is in a good position to capitalize on the surge in online shopping that will continue after Covid, so they raised estimates and pushed the stock to Zacks Rank #2 (Buy) status. However, investors had a very different take on the quarter as shares plunged after the report. Dan has been waiting patiently and it looks like FDX has finally run out of sellers. The editor believes this post-earnings dip provided the perfect opportunity to start a position, especially since FDX appears to have fixed the problems with its European business TNT Express. Learn a lot more about this new addition in the complete commentary. TAZR Trader: Shares of The Trade Desk (TTD) were plunging in early May despite a better-than-expected quarterly report and news of a 10-for-1 stock split. Kevin’s response to the pullback was to add more of this digital-advertising platform operator. Now the stock is exceeding most analyst price targets, so the editor trimmed TTD for a more than 60% return on Monday. He’ll hold onto the rest to see how high it can go. Read the full write-up for more. Blockchain Innovators: Shares of Perion Network (PERI) soared 16.3% on Monday to become the best performer of the day among all ZU names. This global technology company just released strong preliminary second-quarter results, which included a raised guidance for the year. PERI is global technology company that delivers online advertising solutions and search monetization to brands and publishers. The stock has gained more than 30% since Dave added it earlier this month. By the way, Coinbase Global (COIN) also made the top 5 biggest winners today with a rise of 9.9%. Healthcare Innovators: A positive Phase 1 clinical study has shares of Intellia Therapeutics (NTLA) skyrocketing today. With the stock soaring past $130 on a huge short-covering spike, Kevin decided to sell this small CRISPR player for an impressive return of over 90% in less than five months. Don’t be surprised if this name reappears in the portfolio down the road. The editor thinks CAR-T and mRNA therapies will be catalysts for this name moving forward, so he’s looking to reevaluate NTLA shares down the road. See the complete commentary for more specifics. Black Box Trader: More than half of the portfolio was replaced in this week's adjustment. The stocks that were sold on Monday were: • Stellantis N.V. (STLA, +10.6%) • Build-A-Bear Workshop (BBW, +2.6%) • The Chemours Co. (CC, +1.8%) • Tronox Holdings (TROX) • American Axle & Manufacturing (AXL) • Avis Budget Group (CAR) The new buys that filled these spots are: • Alcoa (AA) • Archer Daniels Midland (ADM) • Camping World (CWH) • Foot Locker(FL) • Party City (PRTY) • Sally Beauty (SBH) Read the Black Box Trader’s Guide to learn more about this computer-driven service. Counterstrike: "The big focus this week will be the jobs number on Friday. Investors don't want this data to be too hot as it could create a perception that the Fed would have to get more hawkish. At the same time, if the data is weak, we could see some worries about the upcoming earnings season. "The perfect Goldilocks scenario would be a number right about in line, that would let the Fed hold steady through the end of the year. "Because this number is so important, we shouldn't expect much in direction for the rest of the week. We could grind to all-time highs or drift lower, but I would not expect any outsized moves as the market settles in to a summer nap." -- Jeremy Mullin All the Best, Jim Giaquinto Recommendations from Zacks' Private Portfolios: Believe it or not, this article is not available on the Zacks.com website. The commentary is a partial overview of the daily activity from Zacks' private recommendation services. If you would like to follow our Buy and Sell signals in real time, we've made a special arrangement for readers of this website. Starting today you can see all the recommendations from all of Zacks' portfolios absolutely free for 7 days. Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises (which we've predicted with an astonishing 80%+ accuracy). Click here to "test drive" Zacks Ultimate for FREE >>  Zacks Investment Research.....»»

Category: topSource: zacksSep 21st, 2021

"Damn You To Hell, You Will Not Destroy America" - Here Is The "Spartacus COVID Letter" That"s Gone Viral

"Damn You To Hell, You Will Not Destroy America" - Here Is The 'Spartacus COVID Letter' That's Gone Viral Via The Automatic Earth blog, This is an anonymously posted document by someone who calls themselves Spartacus. Because it’s anonymous, I can’t contact them to ask for permission to publish. So I hesitated for a while, but it’s simply the best document I’ve seen on Covid, vaccines, etc. Whoever Spartacus is, they have a very elaborate knowledge in “the field”. If you want to know a lot more about the no. 1 issue in the world today, read it. And don’t worry if you don’t understand every single word, neither do I. But I learned a lot. The original PDF doc is here: Covid19 – The Spartacus Letter Hello, My name is Spartacus, and I’ve had enough. We have been forced to watch America and the Free World spin into inexorable decline due to a biowarfare attack. We, along with countless others, have been victimized and gaslit by propaganda and psychological warfare operations being conducted by an unelected, unaccountable Elite against the American people and our allies. Our mental and physical health have suffered immensely over the course of the past year and a half. We have felt the sting of isolation, lockdown, masking, quarantines, and other completely nonsensical acts of healthcare theater that have done absolutely nothing to protect the health or wellbeing of the public from the ongoing COVID-19 pandemic. Now, we are watching the medical establishment inject literal poison into millions of our fellow Americans without so much as a fight. We have been told that we will be fired and denied our livelihoods if we refuse to vaccinate. This was the last straw. We have spent thousands of hours analyzing leaked footage from Wuhan, scientific papers from primary sources, as well as the paper trails left by the medical establishment. What we have discovered would shock anyone to their core. First, we will summarize our findings, and then, we will explain them in detail. References will be placed at the end. Summary: COVID-19 is a blood and blood vessel disease. SARS-CoV-2 infects the lining of human blood vessels, causing them to leak into the lungs. Current treatment protocols (e.g. invasive ventilation) are actively harmful to patients, accelerating oxidative stress and causing severe VILI (ventilator-induced lung injuries). The continued use of ventilators in the absence of any proven medical benefit constitutes mass murder. Existing countermeasures are inadequate to slow the spread of what is an aerosolized and potentially wastewater-borne virus, and constitute a form of medical theater. Various non-vaccine interventions have been suppressed by both the media and the medical establishment in favor of vaccines and expensive patented drugs. The authorities have denied the usefulness of natural immunity against COVID-19, despite the fact that natural immunity confers protection against all of the virus’s proteins, and not just one. Vaccines will do more harm than good. The antigen that these vaccines are based on, SARS-CoV- 2 Spike, is a toxic protein. SARS-CoV-2 may have ADE, or antibody-dependent enhancement; current antibodies may not neutralize future strains, but instead help them infect immune cells. Also, vaccinating during a pandemic with a leaky vaccine removes the evolutionary pressure for a virus to become less lethal. There is a vast and appalling criminal conspiracy that directly links both Anthony Fauci and Moderna to the Wuhan Institute of Virology. COVID-19 vaccine researchers are directly linked to scientists involved in brain-computer interface (“neural lace”) tech, one of whom was indicted for taking grant money from China. Independent researchers have discovered mysterious nanoparticles inside the vaccines that are not supposed to be present. The entire pandemic is being used as an excuse for a vast political and economic transformation of Western society that will enrich the already rich and turn the rest of us into serfs and untouchables. COVID-19 Pathophysiology and Treatments: COVID-19 is not a viral pneumonia. It is a viral vascular endotheliitis and attacks the lining of blood vessels, particularly the small pulmonary alveolar capillaries, leading to endothelial cell activation and sloughing, coagulopathy, sepsis, pulmonary edema, and ARDS-like symptoms. This is a disease of the blood and blood vessels. The circulatory system. Any pneumonia that it causes is secondary to that. In severe cases, this leads to sepsis, blood clots, and multiple organ failure, including hypoxic and inflammatory damage to various vital organs, such as the brain, heart, liver, pancreas, kidneys, and intestines. Some of the most common laboratory findings in COVID-19 are elevated D-dimer, elevated prothrombin time, elevated C-reactive protein, neutrophilia, lymphopenia, hypocalcemia, and hyperferritinemia, essentially matching a profile of coagulopathy and immune system hyperactivation/immune cell exhaustion. COVID-19 can present as almost anything, due to the wide tropism of SARS-CoV-2 for various tissues in the body’s vital organs. While its most common initial presentation is respiratory illness and flu-like symptoms, it can present as brain inflammation, gastrointestinal disease, or even heart attack or pulmonary embolism. COVID-19 is more severe in those with specific comorbidities, such as obesity, diabetes, and hypertension. This is because these conditions involve endothelial dysfunction, which renders the circulatory system more susceptible to infection and injury by this particular virus. The vast majority of COVID-19 cases are mild and do not cause significant disease. In known cases, there is something known as the 80/20 rule, where 80% of cases are mild and 20% are severe or critical. However, this ratio is only correct for known cases, not all infections. The number of actual infections is much, much higher. Consequently, the mortality and morbidity rate is lower. However, COVID-19 spreads very quickly, meaning that there are a significant number of severely-ill and critically-ill patients appearing in a short time frame. In those who have critical COVID-19-induced sepsis, hypoxia, coagulopathy, and ARDS, the most common treatments are intubation, injected corticosteroids, and blood thinners. This is not the correct treatment for COVID-19. In severe hypoxia, cellular metabolic shifts cause ATP to break down into hypoxanthine, which, upon the reintroduction of oxygen, causes xanthine oxidase to produce tons of highly damaging radicals that attack tissue. This is called ischemia-reperfusion injury, and it’s why the majority of people who go on a ventilator are dying. In the mitochondria, succinate buildup due to sepsis does the same exact thing; when oxygen is reintroduced, it makes superoxide radicals. Make no mistake, intubation will kill people who have COVID-19. The end-stage of COVID-19 is severe lipid peroxidation, where fats in the body start to “rust” due to damage by oxidative stress. This drives autoimmunity. Oxidized lipids appear as foreign objects to the immune system, which recognizes and forms antibodies against OSEs, or oxidation-specific epitopes. Also, oxidized lipids feed directly into pattern recognition receptors, triggering even more inflammation and summoning even more cells of the innate immune system that release even more destructive enzymes. This is similar to the pathophysiology of Lupus. COVID-19’s pathology is dominated by extreme oxidative stress and neutrophil respiratory burst, to the point where hemoglobin becomes incapable of carrying oxygen due to heme iron being stripped out of heme by hypochlorous acid. No amount of supplemental oxygen can oxygenate blood that chemically refuses to bind O2. The breakdown of the pathology is as follows: SARS-CoV-2 Spike binds to ACE2. Angiotensin Converting Enzyme 2 is an enzyme that is part of the renin-angiotensin-aldosterone system, or RAAS. The RAAS is a hormone control system that moderates fluid volume in the body and in the bloodstream (i.e. osmolarity) by controlling salt retention and excretion. This protein, ACE2, is ubiquitous in every part of the body that interfaces with the circulatory system, particularly in vascular endothelial cells and pericytes, brain astrocytes, renal tubules and podocytes, pancreatic islet cells, bile duct and intestinal epithelial cells, and the seminiferous ducts of the testis, all of which SARS-CoV-2 can infect, not just the lungs. SARS-CoV-2 infects a cell as follows: SARS-CoV-2 Spike undergoes a conformational change where the S1 trimers flip up and extend, locking onto ACE2 bound to the surface of a cell. TMPRSS2, or transmembrane protease serine 2, comes along and cuts off the heads of the Spike, exposing the S2 stalk-shaped subunit inside. The remainder of the Spike undergoes a conformational change that causes it to unfold like an extension ladder, embedding itself in the cell membrane. Then, it folds back upon itself, pulling the viral membrane and the cell membrane together. The two membranes fuse, with the virus’s proteins migrating out onto the surface of the cell. The SARS-CoV-2 nucleocapsid enters the cell, disgorging its genetic material and beginning the viral replication process, hijacking the cell’s own structures to produce more virus. SARS-CoV-2 Spike proteins embedded in a cell can actually cause human cells to fuse together, forming syncytia/MGCs (multinuclear giant cells). They also have other pathogenic, harmful effects. SARS-CoV- 2’s viroporins, such as its Envelope protein, act as calcium ion channels, introducing calcium into infected cells. The virus suppresses the natural interferon response, resulting in delayed inflammation. SARS-CoV-2 N protein can also directly activate the NLRP3 inflammasome. Also, it suppresses the Nrf2 antioxidant pathway. The suppression of ACE2 by binding with Spike causes a buildup of bradykinin that would otherwise be broken down by ACE2. This constant calcium influx into the cells results in (or is accompanied by) noticeable hypocalcemia, or low blood calcium, especially in people with Vitamin D deficiencies and pre-existing endothelial dysfunction. Bradykinin upregulates cAMP, cGMP, COX, and Phospholipase C activity. This results in prostaglandin release and vastly increased intracellular calcium signaling, which promotes highly aggressive ROS release and ATP depletion. NADPH oxidase releases superoxide into the extracellular space. Superoxide radicals react with nitric oxide to form peroxynitrite. Peroxynitrite reacts with the tetrahydrobiopterin cofactor needed by endothelial nitric oxide synthase, destroying it and “uncoupling” the enzymes, causing nitric oxide synthase to synthesize more superoxide instead. This proceeds in a positive feedback loop until nitric oxide bioavailability in the circulatory system is depleted. Dissolved nitric oxide gas produced constantly by eNOS serves many important functions, but it is also antiviral against SARS-like coronaviruses, preventing the palmitoylation of the viral Spike protein and making it harder for it to bind to host receptors. The loss of NO allows the virus to begin replicating with impunity in the body. Those with endothelial dysfunction (i.e. hypertension, diabetes, obesity, old age, African-American race) have redox equilibrium issues to begin with, giving the virus an advantage. Due to the extreme cytokine release triggered by these processes, the body summons a great deal of neutrophils and monocyte-derived alveolar macrophages to the lungs. Cells of the innate immune system are the first-line defenders against pathogens. They work by engulfing invaders and trying to attack them with enzymes that produce powerful oxidants, like SOD and MPO. Superoxide dismutase takes superoxide and makes hydrogen peroxide, and myeloperoxidase takes hydrogen peroxide and chlorine ions and makes hypochlorous acid, which is many, many times more reactive than sodium hypochlorite bleach. Neutrophils have a nasty trick. They can also eject these enzymes into the extracellular space, where they will continuously spit out peroxide and bleach into the bloodstream. This is called neutrophil extracellular trap formation, or, when it becomes pathogenic and counterproductive, NETosis. In severe and critical COVID-19, there is actually rather severe NETosis. Hypochlorous acid building up in the bloodstream begins to bleach the iron out of heme and compete for O2 binding sites. Red blood cells lose the ability to transport oxygen, causing the sufferer to turn blue in the face. Unliganded iron, hydrogen peroxide, and superoxide in the bloodstream undergo the Haber- Weiss and Fenton reactions, producing extremely reactive hydroxyl radicals that violently strip electrons from surrounding fats and DNA, oxidizing them severely. This condition is not unknown to medical science. The actual name for all of this is acute sepsis. We know this is happening in COVID-19 because people who have died of the disease have noticeable ferroptosis signatures in their tissues, as well as various other oxidative stress markers such as nitrotyrosine, 4-HNE, and malondialdehyde. When you intubate someone with this condition, you are setting off a free radical bomb by supplying the cells with O2. It’s a catch-22, because we need oxygen to make Adenosine Triphosphate (that is, to live), but O2 is also the precursor of all these damaging radicals that lead to lipid peroxidation. The correct treatment for severe COVID-19 related sepsis is non-invasive ventilation, steroids, and antioxidant infusions. Most of the drugs repurposed for COVID-19 that show any benefit whatsoever in rescuing critically-ill COVID-19 patients are antioxidants. N-acetylcysteine, melatonin, fluvoxamine, budesonide, famotidine, cimetidine, and ranitidine are all antioxidants. Indomethacin prevents iron- driven oxidation of arachidonic acid to isoprostanes. There are powerful antioxidants such as apocynin that have not even been tested on COVID-19 patients yet which could defang neutrophils, prevent lipid peroxidation, restore endothelial health, and restore oxygenation to the tissues. Scientists who know anything about pulmonary neutrophilia, ARDS, and redox biology have known or surmised much of this since March 2020. In April 2020, Swiss scientists confirmed that COVID-19 was a vascular endotheliitis. By late 2020, experts had already concluded that COVID-19 causes a form of viral sepsis. They also know that sepsis can be effectively treated with antioxidants. None of this information is particularly new, and yet, for the most part, it has not been acted upon. Doctors continue to use damaging intubation techniques with high PEEP settings despite high lung compliance and poor oxygenation, killing an untold number of critically ill patients with medical malpractice. Because of the way they are constructed, Randomized Control Trials will never show any benefit for any antiviral against COVID-19. Not Remdesivir, not Kaletra, not HCQ, and not Ivermectin. The reason for this is simple; for the patients that they have recruited for these studies, such as Oxford’s ludicrous RECOVERY study, the intervention is too late to have any positive effect. The clinical course of COVID-19 is such that by the time most people seek medical attention for hypoxia, their viral load has already tapered off to almost nothing. If someone is about 10 days post-exposure and has already been symptomatic for five days, there is hardly any virus left in their bodies, only cellular damage and derangement that has initiated a hyperinflammatory response. It is from this group that the clinical trials for antivirals have recruited, pretty much exclusively. In these trials, they give antivirals to severely ill patients who have no virus in their bodies, only a delayed hyperinflammatory response, and then absurdly claim that antivirals have no utility in treating or preventing COVID-19. These clinical trials do not recruit people who are pre-symptomatic. They do not test pre-exposure or post-exposure prophylaxis. This is like using a defibrillator to shock only flatline, and then absurdly claiming that defibrillators have no medical utility whatsoever when the patients refuse to rise from the dead. The intervention is too late. These trials for antivirals show systematic, egregious selection bias. They are providing a treatment that is futile to the specific cohort they are enrolling. India went against the instructions of the WHO and mandated the prophylactic usage of Ivermectin. They have almost completely eradicated COVID-19. The Indian Bar Association of Mumbai has brought criminal charges against WHO Chief Scientist Dr. Soumya Swaminathan for recommending against the use of Ivermectin. Ivermectin is not “horse dewormer”. Yes, it is sold in veterinary paste form as a dewormer for animals. It has also been available in pill form for humans for decades, as an antiparasitic drug. The media have disingenuously claimed that because Ivermectin is an antiparasitic drug, it has no utility as an antivirus. This is incorrect. Ivermectin has utility as an antiviral. It blocks importin, preventing nuclear import, effectively inhibiting viral access to cell nuclei. Many drugs currently on the market have multiple modes of action. Ivermectin is one such drug. It is both antiparasitic and antiviral. In Bangladesh, Ivermectin costs $1.80 for an entire 5-day course. Remdesivir, which is toxic to the liver, costs $3,120 for a 5-day course of the drug. Billions of dollars of utterly useless Remdesivir were sold to our governments on the taxpayer’s dime, and it ended up being totally useless for treating hyperinflammatory COVID-19. The media has hardly even covered this at all. The opposition to the use of generic Ivermectin is not based in science. It is purely financially and politically-motivated. An effective non-vaccine intervention would jeopardize the rushed FDA approval of patented vaccines and medicines for which the pharmaceutical industry stands to rake in billions upon billions of dollars in sales on an ongoing basis. The majority of the public are scientifically illiterate and cannot grasp what any of this even means, thanks to a pathetic educational system that has miseducated them. You would be lucky to find 1 in 100 people who have even the faintest clue what any of this actually means. COVID-19 Transmission: COVID-19 is airborne. The WHO carried water for China by claiming that the virus was only droplet- borne. Our own CDC absurdly claimed that it was mostly transmitted by fomite-to-face contact, which, given its rapid spread from Wuhan to the rest of the world, would have been physically impossible. The ridiculous belief in fomite-to-face being a primary mode of transmission led to the use of surface disinfection protocols that wasted time, energy, productivity, and disinfectant. The 6-foot guidelines are absolutely useless. The minimum safe distance to protect oneself from an aerosolized virus is to be 15+ feet away from an infected person, no closer. Realistically, no public transit is safe. Surgical masks do not protect you from aerosols. The virus is too small and the filter media has too large of gaps to filter it out. They may catch respiratory droplets and keep the virus from being expelled by someone who is sick, but they do not filter a cloud of infectious aerosols if someone were to walk into said cloud. The minimum level of protection against this virus is quite literally a P100 respirator, a PAPR/CAPR, or a 40mm NATO CBRN respirator, ideally paired with a full-body tyvek or tychem suit, gloves, and booties, with all the holes and gaps taped. Live SARS-CoV-2 may potentially be detected in sewage outflows, and there may be oral-fecal transmission. During the SARS outbreak in 2003, in the Amoy Gardens incident, hundreds of people were infected by aerosolized fecal matter rising from floor drains in their apartments. COVID-19 Vaccine Dangers: The vaccines for COVID-19 are not sterilizing and do not prevent infection or transmission. They are “leaky” vaccines. This means they remove the evolutionary pressure on the virus to become less lethal. It also means that the vaccinated are perfect carriers. In other words, those who are vaccinated are a threat to the unvaccinated, not the other way around. All of the COVID-19 vaccines currently in use have undergone minimal testing, with highly accelerated clinical trials. Though they appear to limit severe illness, the long-term safety profile of these vaccines remains unknown. Some of these so-called “vaccines” utilize an untested new technology that has never been used in vaccines before. Traditional vaccines use weakened or killed virus to stimulate an immune response. The Moderna and Pfizer-BioNTech vaccines do not. They are purported to consist of an intramuscular shot containing a suspension of lipid nanoparticles filled with messenger RNA. The way they generate an immune response is by fusing with cells in a vaccine recipient’s shoulder, undergoing endocytosis, releasing their mRNA cargo into those cells, and then utilizing the ribosomes in those cells to synthesize modified SARS-CoV-2 Spike proteins in-situ. These modified Spike proteins then migrate to the surface of the cell, where they are anchored in place by a transmembrane domain. The adaptive immune system detects the non-human viral protein being expressed by these cells, and then forms antibodies against that protein. This is purported to confer protection against the virus, by training the adaptive immune system to recognize and produce antibodies against the Spike on the actual virus. The J&J and AstraZeneca vaccines do something similar, but use an adenovirus vector for genetic material delivery instead of a lipid nanoparticle. These vaccines were produced or validated with the aid of fetal cell lines HEK-293 and PER.C6, which people with certain religious convictions may object strongly to. SARS-CoV-2 Spike is a highly pathogenic protein on its own. It is impossible to overstate the danger presented by introducing this protein into the human body. It is claimed by vaccine manufacturers that the vaccine remains in cells in the shoulder, and that SARS- CoV-2 Spike produced and expressed by these cells from the vaccine’s genetic material is harmless and inert, thanks to the insertion of prolines in the Spike sequence to stabilize it in the prefusion conformation, preventing the Spike from becoming active and fusing with other cells. However, a pharmacokinetic study from Japan showed that the lipid nanoparticles and mRNA from the Pfizer vaccine did not stay in the shoulder, and in fact bioaccumulated in many different organs, including the reproductive organs and adrenal glands, meaning that modified Spike is being expressed quite literally all over the place. These lipid nanoparticles may trigger anaphylaxis in an unlucky few, but far more concerning is the unregulated expression of Spike in various somatic cell lines far from the injection site and the unknown consequences of that. Messenger RNA is normally consumed right after it is produced in the body, being translated into a protein by a ribosome. COVID-19 vaccine mRNA is produced outside the body, long before a ribosome translates it. In the meantime, it could accumulate damage if inadequately preserved. When a ribosome attempts to translate a damaged strand of mRNA, it can become stalled. When this happens, the ribosome becomes useless for translating proteins because it now has a piece of mRNA stuck in it, like a lace card in an old punch card reader. The whole thing has to be cleaned up and new ribosomes synthesized to replace it. In cells with low ribosome turnover, like nerve cells, this can lead to reduced protein synthesis, cytopathic effects, and neuropathies. Certain proteins, including SARS-CoV-2 Spike, have proteolytic cleavage sites that are basically like little dotted lines that say “cut here”, which attract a living organism’s own proteases (essentially, molecular scissors) to cut them. There is a possibility that S1 may be proteolytically cleaved from S2, causing active S1 to float away into the bloodstream while leaving the S2 “stalk” embedded in the membrane of the cell that expressed the protein. SARS-CoV-2 Spike has a Superantigenic region (SAg), which may promote extreme inflammation. Anti-Spike antibodies were found in one study to function as autoantibodies and attack the body’s own cells. Those who have been immunized with COVID-19 vaccines have developed blood clots, myocarditis, Guillain-Barre Syndrome, Bell’s Palsy, and multiple sclerosis flares, indicating that the vaccine promotes autoimmune reactions against healthy tissue. SARS-CoV-2 Spike does not only bind to ACE2. It was suspected to have regions that bind to basigin, integrins, neuropilin-1, and bacterial lipopolysaccharides as well. SARS-CoV-2 Spike, on its own, can potentially bind any of these things and act as a ligand for them, triggering unspecified and likely highly inflammatory cellular activity. SARS-CoV-2 Spike contains an unusual PRRA insert that forms a furin cleavage site. Furin is a ubiquitous human protease, making this an ideal property for the Spike to have, giving it a high degree of cell tropism. No wild-type SARS-like coronaviruses related to SARS-CoV-2 possess this feature, making it highly suspicious, and perhaps a sign of human tampering. SARS-CoV-2 Spike has a prion-like domain that enhances its infectiousness. The Spike S1 RBD may bind to heparin-binding proteins and promote amyloid aggregation. In humans, this could lead to Parkinson’s, Lewy Body Dementia, premature Alzheimer’s, or various other neurodegenerative diseases. This is very concerning because SARS-CoV-2 S1 is capable of injuring and penetrating the blood-brain barrier and entering the brain. It is also capable of increasing the permeability of the blood-brain barrier to other molecules. SARS-CoV-2, like other betacoronaviruses, may have Dengue-like ADE, or antibody-dependent enhancement of disease. For those who aren’t aware, some viruses, including betacoronaviruses, have a feature called ADE. There is also something called Original Antigenic Sin, which is the observation that the body prefers to produce antibodies based on previously-encountered strains of a virus over newly- encountered ones. In ADE, antibodies from a previous infection become non-neutralizing due to mutations in the virus’s proteins. These non-neutralizing antibodies then act as trojan horses, allowing live, active virus to be pulled into macrophages through their Fc receptor pathways, allowing the virus to infect immune cells that it would not have been able to infect before. This has been known to happen with Dengue Fever; when someone gets sick with Dengue, recovers, and then contracts a different strain, they can get very, very ill. If someone is vaccinated with mRNA based on the Spike from the initial Wuhan strain of SARS-CoV-2, and then they become infected with a future, mutated strain of the virus, they may become severely ill. In other words, it is possible for vaccines to sensitize someone to disease. There is a precedent for this in recent history. Sanofi’s Dengvaxia vaccine for Dengue failed because it caused immune sensitization in people whose immune systems were Dengue-naive. In mice immunized against SARS-CoV and challenged with the virus, a close relative of SARS-CoV-2, they developed immune sensitization, Th2 immunopathology, and eosinophil infiltration in their lungs. We have been told that SARS-CoV-2 mRNA vaccines cannot be integrated into the human genome, because messenger RNA cannot be turned back into DNA. This is false. There are elements in human cells called LINE-1 retrotransposons, which can indeed integrate mRNA into a human genome by endogenous reverse transcription. Because the mRNA used in the vaccines is stabilized, it hangs around in cells longer, increasing the chances for this to happen. If the gene for SARS-CoV-2 Spike is integrated into a portion of the genome that is not silent and actually expresses a protein, it is possible that people who take this vaccine may continuously express SARS-CoV-2 Spike from their somatic cells for the rest of their lives. By inoculating people with a vaccine that causes their bodies to produce Spike in-situ, they are being inoculated with a pathogenic protein. A toxin that may cause long-term inflammation, heart problems, and a raised risk of cancers. In the long-term, it may also potentially lead to premature neurodegenerative disease. Absolutely nobody should be compelled to take this vaccine under any circumstances, and in actual fact, the vaccination campaign must be stopped immediately. COVID-19 Criminal Conspiracy: The vaccine and the virus were made by the same people. In 2014, there was a moratorium on SARS gain-of-function research that lasted until 2017. This research was not halted. Instead, it was outsourced, with the federal grants being laundered through NGOs. Ralph Baric is a virologist and SARS expert at UNC Chapel Hill in North Carolina. This is who Anthony Fauci was referring to when he insisted, before Congress, that if any gain-of-function research was being conducted, it was being conducted in North Carolina. This was a lie. Anthony Fauci lied before Congress. A felony. Ralph Baric and Shi Zhengli are colleagues and have co-written papers together. Ralph Baric mentored Shi Zhengli in his gain-of-function manipulation techniques, particularly serial passage, which results in a virus that appears as if it originated naturally. In other words, deniable bioweapons. Serial passage in humanized hACE2 mice may have produced something like SARS-CoV-2. The funding for the gain-of-function research being conducted at the Wuhan Institute of Virology came from Peter Daszak. Peter Daszak runs an NGO called EcoHealth Alliance. EcoHealth Alliance received millions of dollars in grant money from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (that is, Anthony Fauci), the Defense Threat Reduction Agency (part of the US Department of Defense), and the United States Agency for International Development. NIH/NIAID contributed a few million dollars, and DTRA and USAID each contributed tens of millions of dollars towards this research. Altogether, it was over a hundred million dollars. EcoHealth Alliance subcontracted these grants to the Wuhan Institute of Virology, a lab in China with a very questionable safety record and poorly trained staff, so that they could conduct gain-of-function research, not in their fancy P4 lab, but in a level-2 lab where technicians wore nothing more sophisticated than perhaps a hairnet, latex gloves, and a surgical mask, instead of the bubble suits used when working with dangerous viruses. Chinese scientists in Wuhan reported being routinely bitten and urinated on by laboratory animals. Why anyone would outsource this dangerous and delicate work to the People’s Republic of China, a country infamous for industrial accidents and massive explosions that have claimed hundreds of lives, is completely beyond me, unless the aim was to start a pandemic on purpose. In November of 2019, three technicians at the Wuhan Institute of Virology developed symptoms consistent with a flu-like illness. Anthony Fauci, Peter Daszak, and Ralph Baric knew at once what had happened, because back channels exist between this laboratory and our scientists and officials. December 12th, 2019, Ralph Baric signed a Material Transfer Agreement (essentially, an NDA) to receive Coronavirus mRNA vaccine-related materials co-owned by Moderna and NIH. It wasn’t until a whole month later, on January 11th, 2020, that China allegedly sent us the sequence to what would become known as SARS-CoV-2. Moderna claims, rather absurdly, that they developed a working vaccine from this sequence in under 48 hours. Stephane Bancel, the current CEO of Moderna, was formerly the CEO of bioMerieux, a French multinational corporation specializing in medical diagnostic tech, founded by one Alain Merieux. Alain Merieux was one of the individuals who was instrumental in the construction of the Wuhan Institute of Virology’s P4 lab. The sequence given as the closest relative to SARS-CoV-2, RaTG13, is not a real virus. It is a forgery. It was made by entering a gene sequence by hand into a database, to create a cover story for the existence of SARS-CoV-2, which is very likely a gain-of-function chimera produced at the Wuhan Institute of Virology and was either leaked by accident or intentionally released. The animal reservoir of SARS-CoV-2 has never been found. This is not a conspiracy “theory”. It is an actual criminal conspiracy, in which people connected to the development of Moderna’s mRNA-1273 are directly connected to the Wuhan Institute of Virology and their gain-of-function research by very few degrees of separation, if any. The paper trail is well- established. The lab-leak theory has been suppressed because pulling that thread leads one to inevitably conclude that there is enough circumstantial evidence to link Moderna, the NIH, the WIV, and both the vaccine and the virus’s creation together. In a sane country, this would have immediately led to the world’s biggest RICO and mass murder case. Anthony Fauci, Peter Daszak, Ralph Baric, Shi Zhengli, and Stephane Bancel, and their accomplices, would have been indicted and prosecuted to the fullest extent of the law. Instead, billions of our tax dollars were awarded to the perpetrators. The FBI raided Allure Medical in Shelby Township north of Detroit for billing insurance for “fraudulent COVID-19 cures”. The treatment they were using? Intravenous Vitamin C. An antioxidant. Which, as described above, is an entirely valid treatment for COVID-19-induced sepsis, and indeed, is now part of the MATH+ protocol advanced by Dr. Paul E. Marik. The FDA banned ranitidine (Zantac) due to supposed NDMA (N-nitrosodimethylamine) contamination. Ranitidine is not only an H2 blocker used as antacid, but also has a powerful antioxidant effect, scavenging hydroxyl radicals. This gives it utility in treating COVID-19. The FDA also attempted to take N-acetylcysteine, a harmless amino acid supplement and antioxidant, off the shelves, compelling Amazon to remove it from their online storefront. This leaves us with a chilling question: did the FDA knowingly suppress antioxidants useful for treating COVID-19 sepsis as part of a criminal conspiracy against the American public? The establishment is cooperating with, and facilitating, the worst criminals in human history, and are actively suppressing non-vaccine treatments and therapies in order to compel us to inject these criminals’ products into our bodies. This is absolutely unacceptable. COVID-19 Vaccine Development and Links to Transhumanism: This section deals with some more speculative aspects of the pandemic and the medical and scientific establishment’s reaction to it, as well as the disturbing links between scientists involved in vaccine research and scientists whose work involved merging nanotechnology with living cells. On June 9th, 2020, Charles Lieber, a Harvard nanotechnology researcher with decades of experience, was indicted by the DOJ for fraud. Charles Lieber received millions of dollars in grant money from the US Department of Defense, specifically the military think tanks DARPA, AFOSR, and ONR, as well as NIH and MITRE. His specialty is the use of silicon nanowires in lieu of patch clamp electrodes to monitor and modulate intracellular activity, something he has been working on at Harvard for the past twenty years. He was claimed to have been working on silicon nanowire batteries in China, but none of his colleagues can recall him ever having worked on battery technology in his life; all of his research deals with bionanotechnology, or the blending of nanotech with living cells. The indictment was over his collaboration with the Wuhan University of Technology. He had double- dipped, against the terms of his DOD grants, and taken money from the PRC’s Thousand Talents plan, a program which the Chinese government uses to bribe Western scientists into sharing proprietary R&D information that can be exploited by the PLA for strategic advantage. Charles Lieber’s own papers describe the use of silicon nanowires for brain-computer interfaces, or “neural lace” technology. His papers describe how neurons can endocytose whole silicon nanowires or parts of them, monitoring and even modulating neuronal activity. Charles Lieber was a colleague of Robert Langer. Together, along with Daniel S. Kohane, they worked on a paper describing artificial tissue scaffolds that could be implanted in a human heart to monitor its activity remotely. Robert Langer, an MIT alumnus and expert in nanotech drug delivery, is one of the co-founders of Moderna. His net worth is now $5.1 billion USD thanks to Moderna’s mRNA-1273 vaccine sales. Both Charles Lieber and Robert Langer’s bibliographies describe, essentially, techniques for human enhancement, i.e. transhumanism. Klaus Schwab, the founder of the World Economic Forum and the architect behind the so-called “Great Reset”, has long spoken of the “blending of biology and machinery” in his books. Since these revelations, it has come to the attention of independent researchers that the COVID-19 vaccines may contain reduced graphene oxide nanoparticles. Japanese researchers have also found unexplained contaminants in COVID-19 vaccines. Graphene oxide is an anxiolytic. It has been shown to reduce the anxiety of laboratory mice when injected into their brains. Indeed, given SARS-CoV-2 Spike’s propensity to compromise the blood-brain barrier and increase its permeability, it is the perfect protein for preparing brain tissue for extravasation of nanoparticles from the bloodstream and into the brain. Graphene is also highly conductive and, in some circumstances, paramagnetic. In 2013, under the Obama administration, DARPA launched the BRAIN Initiative; BRAIN is an acronym for Brain Research Through Advancing Innovative Neurotechnologies®. This program involves the development of brain-computer interface technologies for the military, particularly non-invasive, injectable systems that cause minimal damage to brain tissue when removed. Supposedly, this technology would be used for healing wounded soldiers with traumatic brain injuries, the direct brain control of prosthetic limbs, and even new abilities such as controlling drones with one’s mind. Various methods have been proposed for achieving this, including optogenetics, magnetogenetics, ultrasound, implanted electrodes, and transcranial electromagnetic stimulation. In all instances, the goal is to obtain read or read-write capability over neurons, either by stimulating and probing them, or by rendering them especially sensitive to stimulation and probing. However, the notion of the widespread use of BCI technology, such as Elon Musk’s Neuralink device, raises many concerns over privacy and personal autonomy. Reading from neurons is problematic enough on its own. Wireless brain-computer interfaces may interact with current or future wireless GSM infrastructure, creating neurological data security concerns. A hacker or other malicious actor may compromise such networks to obtain people’s brain data, and then exploit it for nefarious purposes. However, a device capable of writing to human neurons, not just reading from them, presents another, even more serious set of ethical concerns. A BCI that is capable of altering the contents of one’s mind for innocuous purposes, such as projecting a heads-up display onto their brain’s visual center or sending audio into one’s auditory cortex, would also theoretically be capable of altering mood and personality, or perhaps even subjugating someone’s very will, rendering them utterly obedient to authority. This technology would be a tyrant’s wet dream. Imagine soldiers who would shoot their own countrymen without hesitation, or helpless serfs who are satisfied to live in literal dog kennels. BCIs could be used to unscrupulously alter perceptions of basic things such as emotions and values, changing people’s thresholds of satiety, happiness, anger, disgust, and so forth. This is not inconsequential. Someone’s entire regime of behaviors could be altered by a BCI, including such things as suppressing their appetite or desire for virtually anything on Maslow’s Hierarchy of Needs. Anything is possible when you have direct access to someone’s brain and its contents. Someone who is obese could be made to feel disgust at the sight of food. Someone who is involuntarily celibate could have their libido disabled so they don’t even desire sex to begin with. Someone who is racist could be forced to feel delight over cohabiting with people of other races. Someone who is violent could be forced to be meek and submissive. These things might sound good to you if you are a tyrant, but to normal people, the idea of personal autonomy being overridden to such a degree is appalling. For the wealthy, neural laces would be an unequaled boon, giving them the opportunity to enhance their intelligence with neuroprosthetics (i.e. an “exocortex”), and to deliver irresistible commands directly into the minds of their BCI-augmented servants, even physically or sexually abusive commands that they would normally refuse. If the vaccine is a method to surreptitiously introduce an injectable BCI into millions of people without their knowledge or consent, then what we are witnessing is the rise of a tyrannical regime unlike anything ever seen before on the face of this planet, one that fully intends to strip every man, woman, and child of our free will. Our flaws are what make us human. A utopia arrived at by removing people’s free will is not a utopia at all. It is a monomaniacal nightmare. Furthermore, the people who rule over us are Dark Triad types who cannot be trusted with such power. Imagine being beaten and sexually assaulted by a wealthy and powerful psychopath and being forced to smile and laugh over it because your neural lace gives you no choice but to obey your master. The Elites are forging ahead with this technology without giving people any room to question the social or ethical ramifications, or to establish regulatory frameworks that ensure that our personal agency and autonomy will not be overridden by these devices. They do this because they secretly dream of a future where they can treat you worse than an animal and you cannot even fight back. If this evil plan is allowed to continue, it will spell the end of humanity as we know it. Conclusions: The current pandemic was produced and perpetuated by the establishment, through the use of a virus engineered in a PLA-connected Chinese biowarfare laboratory, with the aid of American taxpayer dollars and French expertise. This research was conducted under the absolutely ridiculous euphemism of “gain-of-function” research, which is supposedly carried out in order to determine which viruses have the highest potential for zoonotic spillover and preemptively vaccinate or guard against them. Gain-of-function/gain-of-threat research, a.k.a. “Dual-Use Research of Concern”, or DURC, is bioweapon research by another, friendlier-sounding name, simply to avoid the taboo of calling it what it actually is. It has always been bioweapon research. The people who are conducting this research fully understand that they are taking wild pathogens that are not infectious in humans and making them more infectious, often taking grants from military think tanks encouraging them to do so. These virologists conducting this type of research are enemies of their fellow man, like pyromaniac firefighters. GOF research has never protected anyone from any pandemic. In fact, it has now started one, meaning its utility for preventing pandemics is actually negative. It should have been banned globally, and the lunatics performing it should have been put in straitjackets long ago. Either through a leak or an intentional release from the Wuhan Institute of Virology, a deadly SARS strain is now endemic across the globe, after the WHO and CDC and public officials first downplayed the risks, and then intentionally incited a panic and lockdowns that jeopardized people’s health and their livelihoods. This was then used by the utterly depraved and psychopathic aristocratic class who rule over us as an excuse to coerce people into accepting an injected poison which may be a depopulation agent, a mind control/pacification agent in the form of injectable “smart dust”, or both in one. They believe they can get away with this by weaponizing the social stigma of vaccine refusal. They are incorrect. Their motives are clear and obvious to anyone who has been paying attention. These megalomaniacs have raided the pension funds of the free world. Wall Street is insolvent and has had an ongoing liquidity crisis since the end of 2019. The aim now is to exert total, full-spectrum physical, mental, and financial control over humanity before we realize just how badly we’ve been extorted by these maniacs. The pandemic and its response served multiple purposes for the Elite: Concealing a depression brought on by the usurious plunder of our economies conducted by rentier-capitalists and absentee owners who produce absolutely nothing of any value to society whatsoever. Instead of us having a very predictable Occupy Wall Street Part II, the Elites and their stooges got to stand up on television and paint themselves as wise and all-powerful saviors instead of the marauding cabal of despicable land pirates that they are. Destroying small businesses and eroding the middle class. Transferring trillions of dollars of wealth from the American public and into the pockets of billionaires and special interests. Engaging in insider trading, buying stock in biotech companies and shorting brick-and-mortar businesses and travel companies, with the aim of collapsing face-to-face commerce and tourism and replacing it with e-commerce and servitization. Creating a casus belli for war with China, encouraging us to attack them, wasting American lives and treasure and driving us to the brink of nuclear armageddon. Establishing technological and biosecurity frameworks for population control and technocratic- socialist “smart cities” where everyone’s movements are despotically tracked, all in anticipation of widespread automation, joblessness, and food shortages, by using the false guise of a vaccine to compel cooperation. Any one of these things would constitute a vicious rape of Western society. Taken together, they beggar belief; they are a complete inversion of our most treasured values. What is the purpose of all of this? One can only speculate as to the perpetrators’ motives, however, we have some theories. The Elites are trying to pull up the ladder, erase upward mobility for large segments of the population, cull political opponents and other “undesirables”, and put the remainder of humanity on a tight leash, rationing our access to certain goods and services that they have deemed “high-impact”, such as automobile use, tourism, meat consumption, and so on. Naturally, they will continue to have their own luxuries, as part of a strict caste system akin to feudalism. Why are they doing this? Simple. The Elites are Neo-Malthusians and believe that we are overpopulated and that resource depletion will collapse civilization in a matter of a few short decades. They are not necessarily incorrect in this belief. We are overpopulated, and we are consuming too many resources. However, orchestrating such a gruesome and murderous power grab in response to a looming crisis demonstrates that they have nothing but the utmost contempt for their fellow man. To those who are participating in this disgusting farce without any understanding of what they are doing, we have one word for you. Stop. You are causing irreparable harm to your country and to your fellow citizens. To those who may be reading this warning and have full knowledge and understanding of what they are doing and how it will unjustly harm millions of innocent people, we have a few more words. Damn you to hell. You will not destroy America and the Free World, and you will not have your New World Order. We will make certain of that. *  *  * This PDF document contains 14 pages, followed by another 17 pages of references. For those, please visit the original PDF file at Covid19 – The Spartacus Letter. *  *  * We try to run the Automatic Earth on donations. Since ad revenue has collapsed, you are now not just a reader, but an integral part of the process that builds this site. Thank you for your support. Support the Automatic Earth in virustime. Donate with Paypal, Bitcoin and Patreon. Tyler Durden Mon, 09/27/2021 - 00:00.....»»

Category: dealsSource: nyt3 hr. 14 min. ago

I finally quit my finance job to become a full-time musician - here"s how I"m making the jump

Dane Drewis tried to become a full-time musician a few years ago but fell back on his finance degree. This time, he's making sure it'll be different. Dane Drewis and his guitar. Dane Drewis Dane Drewis is quitting his finance job to pursue music full-time by treating his music like a business. Drewis treats his music like a business and has mapped out a financial strategy to move forward. He recommends acquiring digital production skills for more control over your music. See more stories on Insider's business page. Sometimes you need a nudge to make a leap of faith. But a pandemic lockdown can do the trick, too. Once music gigs dried up during COVID-19 lockdowns, California musician Dane Drewis decided he would quit his corporate finance job and make the jump from part-time to full-time musician. Drewis, who was most recently the VP of finance at design and technology company 14th Round Inc., has done a lot of jobs in his working career: business, finance, waiting tables, and even running a restaurant that Beyoncé invested in.But that list never included music, until now - and that's because he's decided to treat his music like a business venture, not just a side hobby."I'll be turning 39 soon and I've never made a full commitment with music," Drewis told Insider. "I want to be able to look back and say I went all in with music."Drewis, whose parents are both musicians, fell in love with music in college thanks to late-night jam sessions and endless hours practicing guitar alone in his dorm room. But as he took on a professional career, he didn't have the time or energy to go all in. Despite a comfortable salary at his old job and the flexibility to play music on weekends and during evenings, Drewis felt he had to both answer his passion and stop doing what he didn't enjoy. "Honestly I'm tired of doing spreadsheets all day," Drewis said. "I'm ready to share as much happiness and love as possible through committing myself to music."No more safety netsSeveral years ago, Drewis gave up an attempt at becoming a full-time musician because sleeping in his van and living with fewer comforts took its toll. He couldn't secure enough music work to make ends meet and eventually he had to find a full-time job. "Being that broke is stressful and it makes it really hard to be creative," Drewis explained. This time, Drewis has given himself a runway to launch off of - the security of a roof over his head and a nest egg of savings, as well as a more developed financial strategy as opposed to playing music at casinos, weddings, and small-time gigs for low pay."I've done the whole starving artist thing, but it won't be the same this time," Drewis said. "Less scrambling for cash and more consistent work this time, promotional events. I'm treating this like a real business venture."In his previous attempt, Drewis kept his finance degree front and center as his backup plan. The safety net, he said, is ultimately what prevented him from full dedication. "No backup plan this time around," Drewis said. "Before, I was like, 'I can do finance if I need to.' But this time's different. I know for damn sure I don't want to do finance again. That's what's driving me this time."Leveraging digital skills and a business planTo make the jump to full-time musician, Drewis has revamped his digital skills and has used his education to map out a financial strategy for his music business. He shares music on Instagram and is a verified artist on Spotify.He's invested in learning how to produce his own songs rather than relying on a company to produce his music for him - something essential to maintaining creative freedom, Drewis said. A post shared by Dane Drewis (@danedrewis) "I've put a lot of time into learning the software behind music production, tracking and producing my own songs," Drewis said. "I'm taking control over my recordings for my own work."By producing his own music and working on his own timeline, Drewis aims to create original content on a regular basis. Then, he has plans to build out his music-licensing business to get his songs on television commercials and elsewhere. "Ten years ago, I never treated music like a business," Drewis said. "I just saw myself as a singer. But now I see this as a startup company. I know my revenue and expenses. I have a firm business plan."To younger artists looking to make the leap, Drewis recommends becoming as tech-savvy as possible with music production. "[Digital] skill set is the primary currency today," Drewis said. "You want to be your own artist, you want to be able to translate what's in your mind onto the computer and into people's ears, all while making your music sound exactly how you want it to sound." Drewis recommends becoming proficient at Ableton, a production software, as a way of gaining more autonomy as a musician. These tools allow for greater control and customization, he said. Drewis returned from his first international tour in Germany last week, and he has a slew of shows planned for the coming months. His focus remains on building out his digital presence, filming music videos, and growing his audience."For musicians, a big worry is artistic failure," Drewis said. "But a bigger worry, for me, is wondering if I was good enough to really do this. Now's the time to find out." Read the original article on Business Insider.....»»

Category: topSource: businessinsiderSep 25th, 2021

"Immunity As A Service" - The Snake-Oil Salesmen & The COVID-Zero Con

"Immunity As A Service" - The Snake-Oil Salesmen & The COVID-Zero Con Authored by Julius Ruechel via Julius Ruechel.com, The Snake-Oil Salesmen and the COVID-Zero Con: A Classic Bait-And-Switch for a Lifetime of Booster Shots (Immunity as a Service) If a plumber with a lifetime of experience were to tell you that water runs uphill, you would know he is lying and that the lie is not accidental. It is a lie with a purpose. If you can also demonstrate that the plumber knows in advance that the product he is promoting with that lie is snake oil, you have evidence for a deliberate con. And once you understand what's really inside that bottle of snake oil, you will begin to understand the purpose of the con. One of the most common reasons given for mass COVID vaccinations is the idea that if we reach herd immunity through vaccination, we can starve the virus out of existence and get our lives back. It's the COVID-Zero strategy or some variant of it. By now it is abundantly clear from the epidemiological data that the vaccinated are able to both catch and spread the disease. Clearly vaccination isn't going to make this virus disappear. Only a mind that has lost its grasp on reality can fail to see how ridiculous all this has become.  But a tour through pre-COVID science demonstrates that, from day one, long before you and I had even heard of this virus, it was 100% inevitable and 100% predictable that these vaccines would never be capable of eradicating this coronavirus and would never lead to any kind of lasting herd immunity. Even worse, lockdowns and mass vaccination have created a dangerous set of circumstances that interferes with our immune system's ability to protect us against other respiratory viruses. They also risk driving the evolution of this virus towards mutations that are more dangerous to both the vaccinated and the unvaccinated alike. Lockdowns, mass vaccinations, and mass booster shots were never capable of delivering on any of the promises that were made to the public.  And yet, vaccination has been successfully used to control measles and even to eradicate smallpox. So, why not COVID? Immunity is immunity, and a virus is a virus is a virus, right? Wrong! Reality is far more complicated... and more interesting. This Deep Dive exposes why, from day one, the promise of COVID-Zero can only ever have been a deliberately dishonest shell game designed to prey on a lack of public understanding of how our immune systems work and on how most respiratory viruses differ from other viruses that we routinely vaccinate against. We have been sold a fantasy designed to rope us into a pharmaceutical dependency as a deceitful trade-off for access to our lives. Variant by variant. For as long as the public is willing to go along for the ride.  Exposing this story does not require incriminating emails or whistleblower testimony. The story tells itself by diving into the long-established science that every single virologist, immunologist, evolutionary biologist, vaccine developer, and public health official had access to long before COVID began. As is so often the case, the devil is hidden in the details. As this story unfolds it will become clear that the one-two punch of lockdowns and the promise of vaccines as an exit strategy began as a cynical marketing ploy to coerce us into a never-ending regimen of annual booster shots intentionally designed to replace the natural "antivirus security updates" against respiratory viruses that come from hugs and handshakes and from children laughing together at school. We are being played for fools.  This is not to say that there aren't plenty of other opportunists taking advantage of this crisis to pursue other agendas and to tip society into a full-blown police state. One thing quickly morphs into another. But this essay demonstrates that never-ending boosters were the initial motive for this global social-engineering shell game ― the subscription-based business model, adapted for the pharmaceutical industry. "Immunity as a service".  So, let's dive into the fascinating world of immune systems, viruses, and vaccines, layer by layer, to dispel the myths and false expectations that have been created by deceitful public health officials, pharmaceutical lobbyists, and media manipulators. What emerges as the lies are peeled apart is both surprising and more than a little alarming. “Once you eliminate the impossible, whatever remains, no matter how improbable, must be the truth.” - Sherlock Homes”  - Sir Arthur Conan Doyle Table of Contents:     Viral Reservoirs: The Fantasy of Eradication     SARS: The Exception to the Rule?     Fast Mutations: The Fantasy of Control through Herd Immunity     Blind Faith in Central Planning: The Fantasy of Timely Doses     Spiked: The Fantasy of Preventing Infection     Antibodies, B-Cells, and T-Cells: Why Immunity to Respiratory Viruses Fades So Quickly     Manufacturing Dangerous Variants: Virus Mutations Under Lockdown Conditions — Lessons from the 1918 Spanish Flu     Leaky Vaccines, Antibody-Dependent Enhancement, and the Marek Effect     Anti-Virus Security Updates: Cross-Reactive Immunity Through Repeated Exposure     The Not-So-Novel Novel Virus: The Diamond Princess Cruise Ship Outbreak Proved We Have Cross-Reactive Immunity     Mother Knows Best: Vitamin D, Playing in Puddles, and Sweaters     The Paradox: Why COVID-Zero Makes People More Vulnerable to Other Viruses     Introducing Immunity as a Service - A Subscription-Based Business Model for the Pharmaceutical Industry (It was always about the money!)     The Path Forward: Neutralizing the Threat and Bullet-Proofing Society to Prevent This Ever Happening Again. *  *  * Viral Reservoirs: The Fantasy of Eradication Eradication of a killer virus sounds like a noble goal. In some cases it is, such as in the case of the smallpox virus. By 1980 we stopped vaccinating against smallpox because, thanks to widespread immunization, we starved the virus of available hosts for so long that it died out. No-one will need to risk their life on the side effects of a smallpox vaccination ever again because the virus is gone. It is a public health success story. Polio will hopefully be next ― we're getting close.  But smallpox is one of only two viruses (along with rinderpest) that have been eradicated thanks to vaccination. Very few diseases meet the necessary criteria. Eradication is hard and only appropriate for very specific families of viruses. Smallpox made sense for eradication because it was a uniquely human virus ― there was no animal reservoir. By contrast, most respiratory viruses including SARS-CoV-2 (a.k.a. COVID) come from animal reservoirs: swine, birds, bats, etc. As long as there are bats in caves, birds in ponds, pigs in mud baths, and deer living in forests, respiratory viruses are only controllable through individual immunity, but it is not possible to eradicate them. There will always be a near-identical cousin brewing in the wings. Even the current strain of COVID is already cheerfully jumping onwards across species boundaries. According to both National Geographic and Nature magazine, 40% of wild deer tested positive for COVID antibodies in a study conducted in Michigan, Illinois, New York, and Pennsylvania. It has also been documented in wild mink and has already made the species jump to other captive animals including dogs, cats, otters, leopards, tigers, and gorillas. A lot of viruses are not fussy. They happily adapt to new opportunities. Specialists, like smallpox, eventually go extinct. Generalists, like most respiratory viruses, never run out of hosts to keep the infection cycle going, forever. As long as we share this planet with other animals, it is extremely deceitful to give anyone the impression that we can pursue any scorched earth policy that can put this genie back in the bottle. With an outbreak on this global scale, it was clear that we were always going to have to live with this virus. There are over 200 other endemic respiratory viruses that cause colds and flus, many of which circulate freely between humans and other animals. Now there are 201. They will be with us forever, whether we like it or not. SARS: The Exception to the Rule? This all sounds well and good, but the original SARS virus did disappear, with public health measures like contact tracing and strict quarantine measures taking the credit. However, SARS was the exception to the rule. When it made the species jump to humans, it was so poorly adapted to its new human hosts that it had terrible difficulty spreading. This very poor level of adaptation gave SARS a rather unique combination of properties: SARS was extremely difficult to catch (it was never very contagious) SARS made people extremely sick. SARS did not have pre-symptomatic spread. These three conditions made the SARS outbreak easy to control through contact tracing and through the quarantine of symptomatic individuals. SARS therefore never reached the point where it circulated widely among asymptomatic community members.  By contrast, by January/February of 2020 it was clear from experiences in China, Italy, and the outbreak on the Diamond Princess cruise ship (more on that story later) that the unique combination of conditions that made SARS controllable were not going to be the case with COVID. COVID was quite contagious (its rapid spread showed that COVID was already well adapted to spreading easily among its new human hosts), most people would have mild or no symptoms from COVID (making containment impossible), and that it was spreading by aerosols produced by both symptomatic and pre-symptomatic people (making contact tracing a joke). In other words, it was clear by January/February 2020 that this pandemic would follow the normal rules of a readily transmissible respiratory epidemic, which cannot be reined in the way SARS was. Thus, by January/February of 2020, giving the public the impression that the SARS experience could be replicated for COVID was a deliberate lie - this genie was never going back inside the bottle. Fast Mutations: The Fantasy of Control through Herd Immunity Once a reasonably contagious respiratory virus begins circulating widely in a community, herd immunity can never be maintained for very long. RNA respiratory viruses (such as influenza viruses, respiratory syncytial virus (RSV), rhinoviruses, and coronaviruses) all mutate extremely fast compared to viruses like smallpox, measles, or polio. Understanding the difference between something like measles and a virus like COVID is key to understanding the con that is being perpetrated by our health institutions. Bear with me here, I promise not to get too technical. All viruses survive by creating copies of themselves. And there are always a lot of "imperfect copies" — mutations — produced by the copying process itself. Among RNA respiratory viruses these mutations stack up so quickly that there is rapid genetic drift, which continually produces new strains. Variants are normal. Variants are expected. Variants make it virtually impossible to build the impenetrable wall of long-lasting herd immunity required to starve these respiratory viruses out of existence. That's one of several reasons why flu vaccines don't provide long-lasting immunity and have to be repeated annually ― our immune system constantly needs to be updated to keep pace with the inevitable evolution of countless unnamed "variants."  This never-ending conveyor belt of mutations means that everyone's immunity to COVID was always only going to be temporary and only offer partial cross-reactive protection against future re-infections. Thus, from day one, COVID vaccination was always doomed to the same fate as the flu vaccine ― a lifelong regimen of annual booster shots to try to keep pace with "variants" for those unwilling to expose themselves to the risk of a natural infection. And the hope that by the time the vaccines (and their booster shots) roll off the production line, they won't already be out of date when confronted by the current generation of virus mutations.  Genetic drift caused by mutations is much slower in viruses like measles, polio, or smallpox, which is why herd immunity can be used to control these other viruses (or even eradicate them as in the case of smallpox or polio). The reason the common respiratory viruses have such rapid genetic drift compared to these other viruses has much less to do with how many errors are produced during the copying process and much more to do with how many of those "imperfect" copies are actually able to survive and produce more copies.  A simple virus with an uncomplicated attack strategy for taking over host cells can tolerate a lot more mutations than a complex virus with a complicated attack strategy. Complexity and specialization put limits on how many of those imperfect copies have a chance at becoming successful mutations. Simple machinery doesn't break down as easily if there is an imperfection in the mechanical parts. Complicated high-tech machinery will simply not work if there are even minor flaws in precision parts. For example, before a virus can hijack the DNA of a host cell to begin making copies of itself, the virus needs to unlock the cell wall to gain entry. Cellular walls are made of proteins and are coated by sugars; viruses need to find a way to create a doorway through that protein wall. A virus like influenza uses a very simple strategy to get inside ― it locks onto one of the sugars on the outside of the cell wall in order to piggyback a ride as the sugar is absorbed into the cell (cells use sugar as their energy source). It's such a simple strategy that it allows the influenza virus to go through lots of mutations without losing its ability to gain entry to the cell. Influenza's simplicity makes it very adaptable and allows many different types of mutations to thrive as long as they all use the same piggyback entry strategy to get inside host cells. By contrast, something like the measles virus uses a highly specialized and very complicated strategy to gain entry to a host cell. It relies on very specialized surface proteins to break open a doorway into the host cell. It's a very rigid and complex system that doesn't leave a lot of room for errors in the copying process. Even minor mutations to the measles virus will cause changes to its surface proteins, leaving it unable to gain access to a host cell to make more copies of itself. Thus, even if there are lots of mutations, those mutations are almost all evolutionary dead ends, thus preventing genetic drift. That's one of several reasons why both a natural infection and vaccination against measles creates lifetime immunity ― immunity lasts because new variations don't change much over time.  Most RNA respiratory viruses have a high rate of genetic drift because they all rely on relatively simple attack strategies to gain entry to host cells. This allows mutations to stack up quickly without becoming evolutionary dead ends because they avoid the evolutionary trap of complexity.  Coronaviruses use a different strategy than influenza to gain access to host cells. They have proteins on the virus surface (the infamous S-spike protein, the same one that is mimicked by the vaccine injection), which latches onto a receptor on the cell surface (the ACE2 receptor) ― a kind of key to unlock the door. This attack strategy is a little bit more complicated than the system used by influenza, which is probably why genetic drift in coronaviruses is slightly slower than in influenza, but it is still a much much simpler and much less specialized system than the one used by measles. Coronaviruses, like other respiratory viruses, are therefore constantly producing a never-ending conveyor belt of "variants" that make long-lasting herd immunity impossible. Variants are normal. The alarm raised by our public health authorities about "variants" and the feigned compassion of pharmaceutical companies as they rush to develop fresh boosters capable of fighting variants is a charade, much like expressing surprise about the sun rising in the East. Once you got immunity to smallpox, measles, or polio, you had full protection for a few decades and were protected against severe illness or death for the rest of your life. But for fast-mutating respiratory viruses, including coronaviruses, within a few months they are sufficiently different that your previously acquired immunity will only ever offer partial protection against your next exposure. The fast rate of mutation ensures that you never catch the exact same cold or flu twice, just their closely related constantly evolving cousins. What keeps you from feeling the full brunt of each new infection is cross-reactive immunity, which is another part of the story of how you are being conned, which I will come back to shortly.  Blind Faith in Central Planning: The Fantasy of Timely Doses But let's pretend for a moment that a miraculous vaccine could be developed that could give us all 100% sterilizing immunity today. The length of time it takes to manufacture and ship 8 billion doses (and then make vaccination appointments for 8 billion people) ensures that by the time the last person gets their last dose, the never-ending conveyor belt of mutations will have already rendered the vaccine partially ineffective. True sterilizing immunity simply won't ever happen with coronaviruses. The logistics of rolling out vaccines to 8 billion people meant that none of our vaccine makers or public health authorities ever could have genuinely believed that vaccines would create lasting herd immunity against COVID. So, for a multitude of reasons, it was a deliberate lie to give the public the impression that if enough people take the vaccine, it would create lasting herd immunity. It was 100% certain, from day one, that by the time the last dose is administered, the rapid evolution of the virus would ensure that it would already be time to start thinking about booster shots. Exactly like the flu shot. Exactly the opposite of a measles vaccine. Vaccines against respiratory viruses can never provide anything more than a temporary cross-reactive immunity "update" ― they are merely a synthetic replacement for your annual natural exposure to the smorgasbord of cold and flu viruses. Immunity as a service, imposed on society by trickery. The only question was always, how long between booster shots? Weeks, months, years?  Feeling conned yet? Spiked: The Fantasy of Preventing Infection The current crop of COVID vaccines was never designed to provide sterilizing immunity - that's not how they work. They are merely a tool designed to teach the immune system to attack the S-spike protein, thereby priming the immune system to reduce the severity of infection in preparation for your inevitable future encounter with the real virus. They were never capable of preventing infection, nor of preventing spread. They were merely designed to reduce your chance of being hospitalized or dying if you are infected. As former FDA commissioner Scott Gottlieb, who is on Pfizer’s board, said: "the original premise behind these vaccines were [sic] that they would substantially reduce the risk of death and severe disease and hospitalization. And that was the data that came out of the initial clinical trials.” Every first-year medical student knows that you cannot get herd immunity from a vaccine that does not stop infection.  In other words, by their design, these vaccines can neither stop you from catching an infection nor stop you from transmitting the infection to someone else. They were never capable of creating herd immunity. They were designed to protect individuals against severe outcomes if they choose to take them - a tool to provide temporary focused protection for the vulnerable, just like the flu vaccine. Pushing for mass vaccination was a con from day one. And the idea of using vaccine passports to separate the vaccinated from the unvaccinated was also a con from day one. The only impact these vaccine passports have on the pandemic is as a coercive tool to get you to roll up your sleeve. Nothing more. Antibodies, B-Cells, and T-Cells: Why Immunity to Respiratory Viruses Fades So Quickly There are multiple interconnected parts to why immunity to COVID, or any other respiratory virus, is always only temporary. Not only is the virus constantly mutating but immunity itself fades over time, not unlike the way our brains start forgetting how to do complicated math problems unless they keep practicing. This is true for both immunity acquired through natural infection and immunity acquired through vaccination. Our immune systems have a kind of immunological memory ― basically, how long does your immune system remember how to launch an attack against a specific kind of threat. That memory fades over time. For some vaccines, like diphtheria and tetanus, that immunological memory fades very slowly. The measles vaccine protects for life. But for others, like the flu vaccine, that immunological memory fades very quickly. On average, the flu vaccine is only about 40% effective to begin with. And it begins to fade almost immediately after vaccination. By about 150 days (5 months), it reaches zero. Fading immunity after flu shot (Science, April 18th, 2019) The solution to this strange phenomenon lies in the different types of immune system responses that are triggered by a vaccine (or by exposure to the real thing through a natural infection). This has big implications for coronavirus vaccines, but I'll get to that in a moment. First a little background information... A good analogy is to think of our immune system like a medieval army. The first layer of protection began with generalists - guys armed with clubs that would take a swing at everything - they were good for keeping robbers and brigands at bay and for conducting small skirmishes. But if the attack was bigger, then these generalists were quickly overwhelmed, serving as arrow fodder to blunt the attack on the more specialized troops coming up behind them. Spearmen, swordsmen, archers, cavalry, catapult operators, siege tower engineers, and so on. Each additional layer of defense has a more expensive kit and takes ever greater amounts of time to train (an English longbowman took years to build up the necessary skill and strength to become effective). The more specialized a troop is, the more you want to hold them back from the fight unless it's absolutely necessary because they are expensive to train, expensive to deploy, and make a bigger mess when they fight that needs to be cleaned up afterwards. Always keep your powder dry. Send in the arrow fodder first and slowly ramp up your efforts from there. Our immune system relies on a similar kind of layered system of defense. In addition to various non-specific rapid response layers that take out the brigands, like natural killer cells, macrophages, mast cells, and so on, we also have many adaptive (specialized) layers of antibodies (i.e. IgA, IgG, IgM immunoglobulin) and various types of highly specialized white blood cells, like B-cells and T-cells. Some antibodies are released by regular B-cells. Others are released by blood plasma. Then there are memory B-cells, which are capable of remembering previous threats and creating new antibodies long after the original antibodies fade away. And there are various types of T-cells (again with various degrees of immunological memory), like natural killer T-cells, killer T-cells, and helper T-cells, all of which play various roles in detecting and neutralizing invaders. In short, the greater the threat, the more troops are called into the fight. This is clearly a gross oversimplification of all the different interconnected parts of our immune system, but the point is that a mild infection doesn't trigger as many layers whereas a severe infection enlists the help of deeper layers, which are slower to respond but are much more specialized in their attack capabilities. And if those deeper adaptive layers get involved, they are capable of retaining a memory of the threat in order to be able to mount a quicker attack if a repeat attack is recognized in the future. That's why someone who was infected by the dangerous Spanish Flu in 1918 might still have measurable T-cell immunity a century later but the mild bout of winter flu you had a couple of years ago might not have triggered T-cell immunity, even though both may have been caused by versions of the same H1N1 influenza virus. As a rule of thumb, the broader the immune response, the longer immunological memory will last. Antibodies fade in a matter of months, whereas B-cell and T-cell immunity can last a lifetime. Another rule of thumb is that a higher viral load puts more strain on your immune defenses, thus overwhelming the rapid response layers and forcing the immune system to enlist the deeper adaptive layers. That's why nursing homes and hospitals are more dangerous places for vulnerable people than backyard barbeques. That's why feedlot cattle are more vulnerable to viral diseases than cattle on pasture. Viral load matters a lot to how easily the generalist layers are overwhelmed and how much effort your immune system has to make to neutralize a threat. Where the infection happens in the body also matters. For example, an infection in the upper respiratory tract triggers much less involvement from your adaptive immune system than when it reaches your lungs. Part of this is because your upper respiratory tract is already heavily preloaded with large numbers of generalist immunological cells that are designed to attack germs as they enter, which is why most colds and flus never make it deeper into the lungs. The guys with the clubs are capable of handling most of the threats that try to make through the gate. Most of the specialized troops hold back unless they are needed. Catching a dangerous disease like measles produces lifetime immunity because an infection triggers all the deep layers that will retain a memory of how to fight off future encounters with the virus. So does the measles vaccine. Catching a cold or mild flu generally does not.  From an evolutionary point of view, this actually makes a lot of sense. Why waste valuable resources developing long-lasting immunity (i.e. training archers and building catapults) to defend against a virus that did not put you in mortal danger. A far better evolutionary strategy is to evolve a narrower generalist immune response to mild infections (i.e. most cold and flu viruses), which fades quickly once the threat is conquered, but invest in deep long-term broad-based immunity to dangerous infections, which lasts a very long time in case that threat is ever spotted on the horizon again. Considering the huge number of threats our immune systems face, this strategy avoids the trap of spreading immunological memory too thin. Our immunological memory resources are not limitless - long-term survival requires prioritizing our immunological resources. The take-home lesson is that vaccines will, at best, only last as long as immunity acquired through natural infection and will often fade much faster because the vaccine is often only able to trigger a partial immune response compared to the actual infection. So, if the disease itself doesn't produce a broad-based immune response leading to long-lasting immunity, neither will the vaccine. And in most cases, immunity acquired through vaccination will begin to fade much sooner than immunity acquired through a natural infection. Every vaccine maker and public health official knows this despite bizarrely claiming that the COVID vaccines (based on re-creating the S-protein spike instead of using a whole virus) would somehow become the exception to the rule. That was a lie, and they knew it from day one. That should set your alarm bells ringing at full throttle. So, with this little bit of background knowledge under our belts, let's look at what our public health officials and vaccine makers would have known in advance about coronaviruses and coronavirus vaccines when they told us back in the early Spring of 2020 that COVID vaccines were the path back to normality. From a 2003 study [my emphasis]: "Until SARS appeared, human coronaviruses were known as the cause of 15–30% of colds... Colds are generally mild, self-limited infections, and significant increases in neutralizing antibody titer are found in nasal secretions and serum after infection. Nevertheless, some unlucky individuals can be reinfected with the same coronavirus soon after recovery and get symptoms again." In other words, the coronaviruses involved in colds (there were four human coronaviruses before SARS, MERS, and COVID) all trigger such a weak immune response that they do not lead to any long-lasting immunity whatsoever. And why would they if, for most of us, the threat is so minimal that the generalists are perfectly capable of neutralizing the attack. We also know that immunity against coronaviruses is not durable in other animals either. As any farmer knows well, cycles of reinfection with coronaviruses are the rule rather than the exception among their livestock (for example, coronaviruses are a common cause of pneumonia and various types of diarrheal diseases like scours, shipping fever, and winter dysentery in cattle). Annual farm vaccination schedules are therefore designed accordingly. The lack of long-term immunity to coronaviruses is well documented in veterinary research among cattle, poultry, deer, water buffalo, etc. Furthermore, although animal coronavirus vaccines have been on the market for many years, it is well known that "none are completely efficacious in animals". So, like the fading flu vaccine profile I showed you earlier, none of the animal coronavirus vaccines are capable of providing sterilizing immunity (none were capable of stopping 100% of infections, without which you can never achieve herd immunity) and the partial immunity they offered is well known to fade rather quickly. What about immunity to COVID's close cousin, the deadly SARS coronavirus, which had an 11% case fatality rate during the 2003 outbreak? From a 2007 study: "SARS-specific antibodies were maintained for an average of 2 years... SARS patients might be susceptible to reinfection >3 years after initial exposure."  (Bear in mind that, as with all diseases, re-infection does not mean you are necessarily going to get full-blown SARS; fading immunity after a natural infection tends to offer at least some level of partial protection against severe outcomes for a considerable amount of time after you can already be reinfected and spread it to others - more on that later.) And what about MERS, the deadliest coronavirus to date, which made the jump from camels in 2012 and had a fatality rate of around 35%? It triggered the broadest immune response (due to its severity) and also appears to trigger the longest lasting immunity as a result (> 6yrs) Thus, to pretend that there was any chance that herd immunity to COVID would be anything but short-lived was dishonest at best. For most people, immunity was always going to fade quickly. Just like what happens after most other respiratory virus infections. By February 2020, the epidemiological data showed clearly that for most people COVID was a mild coronavirus (nowhere near as severe than SARS or MERS), so it was virtually a certainty that even the immunity from a natural infection would fade within months, not years. It was also a certainty that vaccination was therefore, at best, only ever going to provide partial protection and that this protection would be temporary, lasting on the order of months. This is a case of false and misleading advertising if there ever was one. If I can allow my farming roots to shine through for a moment, I'd like to explain the implications of what was known about animal coronaviruses vaccines. Baby calves are often vaccinated against bovine coronaviral diarrhea shortly after birth if they are born in the spring mud and slush season, but not if they are born in midsummer on lush pastures where the risk of infection is lower. Likewise, bovine coronavirus vaccines are used to protect cattle before they face stressful conditions during shipping, in a feedlot, or in winter feed pens. Animal coronavirus vaccines are thus used as tools to provide a temporary boost in immunity, in very specific conditions, and only for very specific vulnerable categories of animals. After everything I've laid out so far in this text, the targeted use of bovine coronavirus vaccines should surprise no-one. Pretending that our human coronavirus vaccines would be different was nonsense.  The only rational reason why the WHO and public health officials would withhold all that contextual information from the public as they rolled out lockdowns and held forth vaccines as an exit strategy was to whip the public into irrational fear in order to be able to make a dishonest case for mass vaccination when they should have, at most, been focused on providing focused vaccination of the most vulnerable only. That deception was the Trojan Horse to introduce endless mass booster shots as immunity inevitably fades and as new variants replace old ones.  Now, as all the inevitable limitations and problems with these vaccines become apparent (i.e. fading of vaccine-induced immunity, vaccines proving to only be partially effective, the rise of new variants, and the vaccinated population demonstrably catching and spreading the virus ― a.k.a. the leaky vaccine phenomenon), the surprise that our health authorities are showing simply isn't credible. As I have shown you, all this was 100% to be expected. They intentionally weaponized fear and false expectations to unleash a fraudulent bait-and-switch racket of global proportions. Immunity on demand, forever. Manufacturing Dangerous Variants: Virus Mutations Under Lockdown Conditions — Lessons from the 1918 Spanish Flu At this point you may be wondering, if there is no lasting immunity from infection or vaccination, then are public health officials right to roll out booster shots to protect us from severe outcomes even if their dishonest methods to get us to accept them were unethical? Do we need a lifetime regimen of booster shots to keep us safe from a beast to which we cannot develop durable long-term immunity? The short answer is no.  Contrary to what you might think, the rapid evolution of RNA respiratory viruses actually has several important benefits for us as their involuntary hosts, which protects us without the benefit of broad lifelong immunity. One of those benefits has to do with the natural evolution of the virus towards less dangerous variants. The other is the cross-reactive immunity that comes from frequent re-exposure to closely related "cousins". I'm going to peel apart both of these topics in order to show you the remarkable system that nature designed to keep us safe... and to show you how the policies being forced on us by our public health authorities are knowingly interfering with this system. They are creating a dangerous situation that increases our risk to other respiratory viruses (not just to COVID) and may even push the COVID virus to evolve to become more dangerous to both the unvaccinated and the vaccinated. There are growing signs that this nightmare scenario has already begun.  “In this present crisis, government is not the solution to our problem; government is the problem."  - President Ronald Reagan in 1981. Let's start with the evolutionary pressures that normally drive viruses towards becoming less dangerous over time. A virus depends on its host to spread it. A lively host is more useful than a bedridden or dead one because a lively host can spread the virus further and will still be around to catch future mutations. Viruses risk becoming evolutionary dead ends if they kill or immobilize their hosts. Plagues came, killed, and then were starved out of existence because their surviving hosts had all acquired herd immunity. Colds come and go every year because their hosts are lively, easily spread the viruses around, and never acquire long-lasting immunity so that last year's hosts can also serve as next year's hosts ― only those who have weak immune systems have much to worry about. In other words, under normal conditions, mutations that are more contagious but less deadly have a survival advantage over less contagious and more deadly variations. From the virus' point of view, the evolutionary golden mean is reached when it can easily infect as many hosts as possible without reducing their mobility and without triggering long-term immunity in most of their hosts. That's the ticket to setting up a sustainable cycle of reinfection, forever. Viruses with slow genetic drift and highly specialized reproductive strategies, like polio or measles, can take centuries or longer to become less deadly and more contagious; some may never reach the relatively harmless status of a cold or mild flu virus (by harmless I mean harmless to the majority of the population despite being extremely dangerous to those with weak or compromised immune systems). But for viruses with fast genetic drift, like respiratory viruses, even a few months can make a dramatic difference. Rapid genetic drift is one of the reasons why the Spanish Flu stopped being a monster disease, but polio and measles haven't. And anyone with training in virology or immunology understands this!  We often speak of evolutionary pressure as though it forces an organism to adapt. In reality, a simple organism like a virus is utterly blind to its environment — all it does is blindly produce genetic copies of itself. "Evolutionary pressure" is actually just a fancy way of saying that environmental conditions will determine which of those millions of copies survives long enough to produce even more copies of itself.  A human adapts to its environment by altering its behaviour (that's one type of adaptation). But the behaviour of a single viral particle never changes. A virus "adapts" over time because some genetic copies with one set of mutations survive and spread faster than other copies with a different set of mutations. Adaptation in viruses has to be seen exclusively through the lens of changes from one generation of virus to the next based on which mutations have a competitive edge over others. And that competitive edge will vary depending on the kinds of environmental conditions a virus encounters. So, fear mongering about the Delta variant being even more contagious leaves out the fact that this is exactly what you would expect as a respiratory virus adapts to its new host species. We would expect new variants to be more contagious but less deadly as the virus fades to become just like the other 200+ respiratory viruses that cause common colds and flus.  That's also why the decision to lock down the healthy population is so sinister. Lockdowns, border closures, and social distancing rules reduced spread among the healthy population, thus creating a situation where mutations produced among the healthy would become sufficiently rare that they might be outnumbered by mutations circulating among the bedridden. Mutations circulating among the healthy are, by definition, going to be the least dangerous mutations since they did not make their hosts s.....»»

Category: blogSource: zerohedgeSep 25th, 2021

Charging Up Your Portfolio with Electric Vehicles

Whether its the government, Wall Street investors or even traditional automakers; everybody is seeing tremendous potential in EVs. Ben Rains will show you how to capitalize on this burgeoning space, which grew over 160% worldwide in the first half of 2021. The U.S. Senate passed a $1 trillion bipartisan infrastructure bill in early August, with billions set to flow into various sectors, from more traditional areas such as roads to modern green energy initiatives. The clean energy efforts are part of a larger push within the U.S and other wealthy nations to speed up the transition away from fossil fuels throughout every corner of the economy.The green energy age isn’t complete without electric vehicles (EVs) dominating streets and highways, and the U.S. still has miles of road to travel in order to get there.Washington’s Focus on EVs The White House and Washington have put a spotlight on electric vehicles as part of a longer-term greener movement. President Biden signed an EV-focused executive order in August that hopes to spur rapid adoption. The non-binding goal aims to have all-electric, hydrogen-fuel cell, and plug-in hybrid vehicles make up 50% of U.S. sales by 2030.In order to reach this voluntary benchmark, automakers called for federal support for EV charging stations, various consumer tax incentives, and other pro-electric initiatives. Elsewhere, the Senate’s $1 trillion bill allots $7.5 billion for states and municipalities to build EV charging stations. The legislative effort also includes over $6 billion in grants for battery production, development, and recycling.The projected funding is less than President Biden called for in March when his administration set a goal of building 500,000 public chargers by 2030. There are currently roughly 48,000 public EV charging stations and over 120,000 charging ports in the U.S., according to U.S. Department of Energy data.These levels don’t come close to supporting rapid EV adoption. Federal, state, and local governments must work with automakers, charger technology companies, and various other stakeholders in order for EVs to start driving American automotive sales anytime soon.Despite all of the hype, the U.S. and the world has barely scratched the EV surface. The nascent nature provides plenty of profitable investment opportunities if you know where to look...Continued . . .------------------------------------------------------------------------------------------------------Zacks’ Top Infrastructure Picks (Grab These for Q4 and Beyond)Our research has identified 5 stocks that are set to surge due to the massive new infrastructure bill. This is the largest bill of its kind in decades, giving investors a chance at tremendous gains.Zacks’s just-updated special report, How to Profit from Trillions in Spending for Infrastructure, is designed to help you profit from the most promising “American Upgrade” stocks. Some infrastructure stocks have recently soared as much as +81%... +150%... even +248%.¹ The stocks in this report could be just as lucrative. Don't delay: this Special Report is only available until Sunday, September 26.See 5 Top Infrastructure Stocks Now >>------------------------------------------------------------------------------------------------------The Current EV Market Gasoline-powered vehicles remain by far the most popular means of transportation. Electric vehicles made up only 2% of U.S. sales last year and expanded to a little over 3% in recent months. Limited market share is part of the reason why Wall Street is excited even if the electric/hybrid space doesn’t get close to 50% market share by 2030.Tesla proved there’s demand for EVs in the U.S. and its success on the road and in the stock market forced every established auto company to go all-in on electric. Plus, plenty of newcomers, some of which are publicly traded, are ramping up production on sleek new EVs of all shapes and sizes. It will be difficult to recreate Tesla’s meteoric run, but a few standout startups are starting to make their case.Most major automakers plan to offer many of their current models as EVs within the next decade, while rolling out EV-only cars, SUVs, and trucks. Established auto titans, perhaps ambitiously, aim to generate upwards of 50% of global sales from EVs by 2030.One historic firm is revamping its entire business around EVs. The company said earlier this year it aims to have 40% of its global volume be all electric by 2030 and it expects to spend more than $30 billion on electrification during this stretch. The firm’s early efforts have already paid off in terms of actual sales and its surging stock price.Auto giants in both luxury and mass markets will start eating away at Tesla’s current dominance. There are plenty of reasons to believe this could happen somewhat quickly. A few select stocks will capture a budding corner of the EV market Tesla has little chance of controlling. The ability to meet the coming demand from commercial customers such as contractors, construction companies, police departments, and other government fleets is set to boost a few well-known companies in particular.Where’s the Money  New light-vehicle sales in the U.S. are set to climb around 13% to reach 16.3 million in 2021. EV sales are projected to blow away the broader industry-wide expansion. For instance, global EV sales already skyrocketed over 160% in the first half of 2021 against a pandemic-hit period.Tesla led the charge, accounting for about 14% of the global market during this stretch, but its share slipped compared to last year. A few global automakers are already in Elon Musk’s rearview mirror despite the huge head start, while smaller, highly affordable brands are dominating EV sales in China and other Asian nations.Along with investing in pure-play electric vehicle companies, Wall Street and the industry are pouring money into the technology side of the business. This is vital since EVs rely heavily on interconnected technology, remote software updates, high-tech touch screens, and much more. One firm in September poached a former Tesla executive from Apple—which has its own EV aspirations—because EVs are closer to supercomputers on wheels than traditional cars.EVs will also provide automakers with more consistent revenue streams, via remote monitoring, constant software updates, and other futuristic maintenance necessities. And it’s hardly just the automakers who stand to benefit. Smaller tech companies are already profiting from advanced radar navigation and more, and many are hot acquisition targets. Batteries and Chargers  EV motors are clearly essential cogs, but high-tech batteries are perhaps the most vital components. Continued progress on the energy storage and range fronts will help determine how quickly the market can grow.Wall Street is also laser-focused on lithium, with the commodity making a case to become a “new oil.” Lithium-ion batteries are already used in most portable consumer electronics such as smartphones, and nearly all electric vehicles run on rechargeable lithium-ion batteries.From startups to Tesla, companies are working on next-generation battery technologies, including solid-state batteries and new cell formats. Like many cutting-edge industries, there are likely game-changing batteries coming down the pike soon that few will have imagined possible.Alongside batteries, an EV-heavy future is only possible if consumers can drive anywhere they normally would or make that same big road trip, without needing to plan their route around chargers. EV chargers are often classified in three categories: Level 1, Level 2, and Level 3 or DC fast chargers. The first two are common for home-based charging, while the fittingly named Level 3 fast chargers require as much as $100,000 or more per station in upfront capital.There are over 100 EV charging companies in North America alone. Firms able to create faster chargers that mimic speeds closer to filling up a tank of gas will be surefire superstars, while companies able to roll out the most chargers, akin to gas stations, could become stable green energy players for decades.5 Stocks to Electrify Your Portfolio Electric vehicles and EV-related technologies are some of the most promising spaces investors can target for long-term gains. Consumers are demanding more electric options and manufacturers are rising to the occasion.And as discussed above, the government is driving hard toward a clean energy future. The infrastructure bill passed by the Senate last month could earmark billions of dollars to make EVs even more accessible – and you might be surprised at which stocks might benefit most.To help you make the most of this opportunity, Zacks has just updated our special report, How to Profit from Trillions in Spending for Infrastructure.The report reveals 5 stocks primed for big price moves, including an EV stock no one is thinking about. The company has a new CEO, a new focus on cutting edge tech and earnings that are projected to skyrocket 300%.I encourage you to check out the 5 stocks right away. The infrastructure bill could be a powerful catalyst, but these companies are strong enough to deliver significant gains on their own.Don’t delay. This Special Report is only available until Sunday, September 26.Click here to claim your copy of How to Profit from Trillions in Spending for Infrastructure >>Good Investing,Ben RainsStock Strategist¹ The results listed above are not (or may not be) representative of the performance of all selections made by Zacks Investment Research's newsletter editors and may represent the partial close of a position.  Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksSep 24th, 2021

Bryn Mawr Bank (BMTC) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bryn Mawr Bank (BMTC) have what it takes? Let's find out. Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures a dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases.Bryn Mawr Bank in FocusBased in Bryn Mawr, Bryn Mawr Bank (BMTC) is in the Finance sector, and so far this year, shares have seen a price change of 36%. Currently paying a dividend of $0.28 per share, the company has a dividend yield of 2.69%. In comparison, the Banks - Northeast industry's yield is 2.09%, while the S&P 500's yield is 1.41%.Taking a look at the company's dividend growth, its current annualized dividend of $1.12 is up 5.7% from last year. Bryn Mawr Bank has increased its dividend 5 times on a year-over-year basis over the last 5 years for an average annual increase of 6.66%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. Bryn Mawr Bank's current payout ratio is 32%. This means it paid out 32% of its trailing 12-month EPS as dividend.Looking at this fiscal year, BMTC expects solid earnings growth. The Zacks Consensus Estimate for 2021 is $2.76 per share, with earnings expected to increase 68.29% from the year ago period.Bottom LineInvestors like dividends for many reasons; they greatly improve stock investing profits, decrease overall portfolio risk, and carry tax advantages, among others. It's important to keep in mind that not all companies provide a quarterly payout.For instance, it's a rare occurrence when a tech start-up or big growth business offers their shareholders a dividend. It's more common to see larger companies with more established profits give out dividends. Income investors must be conscious of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. With that in mind, BMTC is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of 3 (Hold). Time to Invest in Legal Marijuana If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027. After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%. You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.Today, Download Marijuana Moneymakers FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bryn Mawr Bank Corporation (BMTC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksSep 24th, 2021

Why MDU Resources (MDU) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does MDU Resources (MDU) have what it takes? Let's find out. Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that measures the dividend as a percent of the current stock price. Many academic studies show that dividends make up large portions of long-term returns, and in many cases, dividend contributions surpass one-third of total returns.MDU Resources in FocusBased in Bismarck, MDU Resources (MDU) is in the Utilities sector, and so far this year, shares have seen a price change of 11.92%. Currently paying a dividend of $0.21 per share, the company has a dividend yield of 2.88%. In comparison, the Utility - Gas Distribution industry's yield is 3.03%, while the S&P 500's yield is 1.41%.Taking a look at the company's dividend growth, its current annualized dividend of $0.85 is up 1.8% from last year. In the past five-year period, MDU Resources has increased its dividend 5 times on a year-over-year basis for an average annual increase of 2.54%. Any future dividend growth will depend on both earnings growth and the company's payout ratio; a payout ratio is the proportion of a firm's annual earnings per share that it pays out as a dividend. MDU Resources's current payout ratio is 41%. This means it paid out 41% of its trailing 12-month EPS as dividend.Looking at this fiscal year, MDU expects solid earnings growth. The Zacks Consensus Estimate for 2021 is $2.12 per share, which represents a year-over-year growth rate of 8.72%.Bottom LineInvestors like dividends for a variety of different reasons, from tax advantages and decreasing overall portfolio risk to considerably improving stock investing profits. However, not all companies offer a quarterly payout.High-growth firms or tech start-ups, for example, rarely provide their shareholders a dividend, while larger, more established companies that have more secure profits are often seen as the best dividend options. Income investors must be conscious of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. With that in mind, MDU is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of 3 (Hold). Time to Invest in Legal Marijuana If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027. After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%. You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.Today, Download Marijuana Moneymakers FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MDU Resources Group, Inc. (MDU): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksSep 24th, 2021

AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out. Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures a dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases.AbbVie in FocusBased in North Chicago, AbbVie (ABBV) is in the Medical sector, and so far this year, shares have seen a price change of 0.2%. Currently paying a dividend of $1.3 per share, the company has a dividend yield of 4.84%. In comparison, the Large Cap Pharmaceuticals industry's yield is 2.53%, while the S&P 500's yield is 1.41%.Taking a look at the company's dividend growth, its current annualized dividend of $5.20 is up 10.2% from last year. AbbVie has increased its dividend 5 times on a year-over-year basis over the last 5 years for an average annual increase of 20.82%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. AbbVie's current payout ratio is 44%. This means it paid out 44% of its trailing 12-month EPS as dividend.Looking at this fiscal year, ABBV expects solid earnings growth. The Zacks Consensus Estimate for 2021 is $12.64 per share, with earnings expected to increase 19.70% from the year ago period.Bottom LineInvestors like dividends for many reasons; they greatly improve stock investing profits, decrease overall portfolio risk, and carry tax advantages, among others. It's important to keep in mind that not all companies provide a quarterly payout.For instance, it's a rare occurrence when a tech start-up or big growth business offers their shareholders a dividend. It's more common to see larger companies with more established profits give out dividends. Income investors must be conscious of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. With that in mind, ABBV is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of 3 (Hold). Time to Invest in Legal Marijuana If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027. After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%. You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.Today, Download Marijuana Moneymakers FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksSep 24th, 2021

Are You Looking for a High-Growth Dividend Stock? Cummins (CMI) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cummins (CMI) have what it takes? Let's find out. All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures a dividend as a percent of the current stock price. Many academic studies show that dividends make up large portions of long-term returns, and in many cases, dividend contributions surpass one-third of total returns.Cummins in FocusCummins (CMI) is headquartered in Columbus, and is in the Auto-Tires-Trucks sector. The stock has seen a price change of 0.54% since the start of the year. Currently paying a dividend of $1.45 per share, the company has a dividend yield of 2.54%. In comparison, the Automotive - Internal Combustion Engines industry's yield is 1.23%, while the S&P 500's yield is 1.41%.Looking at dividend growth, the company's current annualized dividend of $5.80 is up 9.8% from last year. In the past five-year period, Cummins has increased its dividend 5 times on a year-over-year basis for an average annual increase of 7.31%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. Cummins's current payout ratio is 36%, meaning it paid out 36% of its trailing 12-month EPS as dividend.Earnings growth looks solid for CMI for this fiscal year. The Zacks Consensus Estimate for 2021 is $16.37 per share, with earnings expected to increase 36.30% from the year ago period.Bottom LineFrom greatly improving stock investing profits and reducing overall portfolio risk to providing tax advantages, investors like dividends for a variety of different reasons. However, not all companies offer a quarterly payout.For instance, it's a rare occurrence when a tech start-up or big growth business offers their shareholders a dividend. It's more common to see larger companies with more established profits give out dividends. Income investors have to be mindful of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. With that in mind, CMI is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of 3 (Hold). Time to Invest in Legal Marijuana If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027. After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%. You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.Today, Download Marijuana Moneymakers FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cummins Inc. (CMI): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksSep 24th, 2021

Are You Looking for a High-Growth Dividend Stock? Caterpillar (CAT) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Caterpillar (CAT) have what it takes? Let's find out. All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that measures the dividend as a percent of the current stock price. Many academic studies show that dividends make up large portions of long-term returns, and in many cases, dividend contributions surpass one-third of total returns.Caterpillar in FocusCaterpillar (CAT) is headquartered in Deerfield, and is in the Industrial Products sector. The stock has seen a price change of 8.02% since the start of the year. Currently paying a dividend of $1.11 per share, the company has a dividend yield of 2.26%. In comparison, the Manufacturing - Construction and Mining industry's yield is 0.93%, while the S&P 500's yield is 1.41%.Taking a look at the company's dividend growth, its current annualized dividend of $4.44 is up 7.8% from last year. Caterpillar has increased its dividend 3 times on a year-over-year basis over the last 5 years for an average annual increase of 8.63%. Any future dividend growth will depend on both earnings growth and the company's payout ratio; a payout ratio is the proportion of a firm's annual earnings per share that it pays out as a dividend. Caterpillar's current payout ratio is 46%. This means it paid out 46% of its trailing 12-month EPS as dividend.CAT is expecting earnings to expand this fiscal year as well. The Zacks Consensus Estimate for 2021 is $10.08 per share, with earnings expected to increase 53.66% from the year ago period.Bottom LineInvestors like dividends for a variety of different reasons, from tax advantages and decreasing overall portfolio risk to considerably improving stock investing profits. But, not every company offers a quarterly payout.For instance, it's a rare occurrence when a tech start-up or big growth business offers their shareholders a dividend. It's more common to see larger companies with more established profits give out dividends. During periods of rising interest rates, income investors must be mindful that high-yielding stocks tend to struggle. With that in mind, CAT is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of 3 (Hold). Time to Invest in Legal Marijuana If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027. After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%. You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.Today, Download Marijuana Moneymakers FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Caterpillar Inc. (CAT): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksSep 24th, 2021

Are You Looking for a High-Growth Dividend Stock? Union Pacific (UNP) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Union Pacific (UNP) have what it takes? Let's find out. Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that measures the dividend as a percent of the current stock price. Many academic studies show that dividends make up large portions of long-term returns, and in many cases, dividend contributions surpass one-third of total returns.Union Pacific in FocusBased in Omaha, Union Pacific (UNP) is in the Transportation sector, and so far this year, shares have seen a price change of -3.12%. The railroad is currently shelling out a dividend of $1.07 per share, with a dividend yield of 2.12%. This compares to the Transportation - Rail industry's yield of 1.08% and the S&P 500's yield of 1.41%.In terms of dividend growth, the company's current annualized dividend of $4.28 is up 10.3% from last year. Over the last 5 years, Union Pacific has increased its dividend 5 times on a year-over-year basis for an average annual increase of 14.93%. Future dividend growth will depend on earnings growth as well as payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. Union Pacific's current payout ratio is 47%. This means it paid out 47% of its trailing 12-month EPS as dividend.Looking at this fiscal year, UNP expects solid earnings growth. The Zacks Consensus Estimate for 2021 is $10 per share, representing a year-over-year earnings growth rate of 22.10%.Bottom LineFrom greatly improving stock investing profits and reducing overall portfolio risk to providing tax advantages, investors like dividends for a variety of different reasons. It's important to keep in mind that not all companies provide a quarterly payout.For instance, it's a rare occurrence when a tech start-up or big growth business offers their shareholders a dividend. It's more common to see larger companies with more established profits give out dividends. During periods of rising interest rates, income investors must be mindful that high-yielding stocks tend to struggle. With that in mind, UNP is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of 3 (Hold). Time to Invest in Legal Marijuana If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027. After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%. You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.Today, Download Marijuana Moneymakers FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Union Pacific Corporation (UNP): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksSep 24th, 2021

Why Hanover Insurance Group (THG) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Hanover Insurance Group (THG) have what it takes? Let's find out. All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that measures the dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases.Hanover Insurance Group in FocusHanover Insurance Group (THG) is headquartered in Worcester, and is in the Finance sector. The stock has seen a price change of 13.4% since the start of the year. The insurance company is paying out a dividend of $0.7 per share at the moment, with a dividend yield of 2.11% compared to the Insurance - Property and Casualty industry's yield of 1% and the S&P 500's yield of 1.41%.In terms of dividend growth, the company's current annualized dividend of $2.80 is up 5.7% from last year. Over the last 5 years, Hanover Insurance Group has increased its dividend 5 times on a year-over-year basis for an average annual increase of 9.06%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. Right now, Hanover Insurance's payout ratio is 28%, which means it paid out 28% of its trailing 12-month EPS as dividend.Earnings growth looks solid for THG for this fiscal year. The Zacks Consensus Estimate for 2021 is $9.53 per share, with earnings expected to increase 2.25% from the year ago period.Bottom LineFrom greatly improving stock investing profits and reducing overall portfolio risk to providing tax advantages, investors like dividends for a variety of different reasons. But, not every company offers a quarterly payout.For instance, it's a rare occurrence when a tech start-up or big growth business offers their shareholders a dividend. It's more common to see larger companies with more established profits give out dividends. Income investors must be conscious of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. That said, they can take comfort from the fact that THG is not only an attractive dividend play, but is also a compelling investment opportunity with a Zacks Rank of #2 (Buy). Time to Invest in Legal Marijuana If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027. After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%. You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.Today, Download Marijuana Moneymakers FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Hanover Insurance Group, Inc. (THG): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksSep 24th, 2021

Civilized founders pushed out

Welcome to Insider Cannabis, where we're bringing you an inside look at the deals, trends, and personalities driving the multibillion-dollar cannabis boom. As the legal cannabis market grows in the US, there are many ways for investors to gain exposure to the industry. Bloomberg Creative/Getty Images Welcome to Insider Cannabis, our weekly newsletter where we're bringing you an inside look at the deals, trends, and personalities driving the multibillion-dollar global cannabis boom.Sign up here to get it in your inbox every week.Hello everyone,In some respects, the fight over how to legalize cannabis is a microcosm of larger social debates, pitting social justice activists against more free-market-oriented folks. Take the debate this week over the SAFE Banking Act. The cannabis banking bill passed the House for the fifth time last night. This go-around, language from the bill - which would open up the banking system to cannabis companies and allow consumers to pay with credit cards - was shoehorned into the National Defense Authorization Act.The NDAA usually passes the Senate without much fanfare. But Senate Majority Leader Chuck Schumer, Sen. Ron Wyden, and Sen. Cory Booker have their own more comprehensive cannabis bill, The Cannabis Opportunity and Administration Act. Booker has said that he opposes adding cannabis banking protections to the Senate's version of the NDAA ahead of broader criminal justice reforms.It remains to be seen whether SAFE will be included in the Senate's version of the NDAA. Many cannabis activists say that the SAFE Act would only help banks and large cannabis companies make more money in the industry. They'd rather see full-scale legalization or at least record expungement and other criminal and social justice measures passed first.But supporters of the SAFE Act say it's a necessary tool to help protect and grow small businesses since many social equity license holders are unable to get loans or open lines of credit to start their businesses, and that dealing in all cash is a safety risk. In other news, Amazon doubled down on its support for cannabis legalization and said it was lobbying the federal government for legalization. Aurora Cannabis closed a major facility and cut around 8% of its workforce. The company delayed its earnings until next week. Tilray closed its Nanaimo, British Columbia facility as well. California will be adding a cannabis competition to its state fair, where farmers will show off their best buds. I'll be moderating a panel about the New York cannabis opportunity at the Prohibition Partners x Business of Cannabis conference in New York City on Wednesday, September 29. I'm looking forward to seeing many of you in person, and let me know if you'll be around. - Jeremy Berke (@jfberke)If you like what you read, share this newsletter with your colleagues, friends, boss, spouse, strangers on the internet, or whomever else would like a weekly dose of cannabis news. Here's what we wrote about this week:Investors are pushing out the founders of troubled cannabis startup Civilized. We got ahold of the full memo.Investors are pushing Civilized founders Derek and Terri Riedle out of the company, according to a memo circulated among investors on Monday and obtained by Insider. The investors say the founders, Derek and Terri Riedle, saddled the company with debt.A startup accelerator that's worked with J&J and L'Oréal is getting into psychedelics as the industry goes mainstreamA new accelerator program is targeting early-stage ancillary startups focused on psychedelics, in the latest sign that psychedelics are entering the mainstream and that funding dollars are trailing closely behind. The House just passed cannabis reforms as part of a defense bill. Here's what would change for businesses and their customers.The US House of Representatives has passed the Secure and Fair Enforcement Banking Act, or SAFE Banking Act, yet again.Lawmakers tucked the cannabis banking bill into the National Defense Authorization Act that passed lower chamber on Thursday. It's not clear whether the Senate will include cannabis reforms in its version of the defense package once the upper chamber takes it up. Executive movesNew York Governor Kathy Hochul on Wednesday announced two more appointees - Reuben R. McDaniel, III and Jessica Garcia - to the board of the Office of Cannabis Management, the regulatory body responsible for building out the adult-use cannabis industry in the state. Deals, launches, and IPOsCannabis tech company Dispense said on Tuesday that it had raised a $2 million seed round led by NextView Ventures and Poseidon Asset Management.Michigan-based cannabis company SKYMINT said on Tuesday that it raised $78 million and acquired 3Fifteen Cannabis. Investors in the round include Tropics LP, an affiliate of Sundial Growers' JV SunStream Bancorp Inc., and Merida Capital Holdings.Christine De La Rosa, the CEO of The People's Ecosystem, is raising a $50 million fund to invest in BIPOC and women-led cannabis businesses. Psychedelics company Delic Holdings Corp said on Monday it would acquire Ketamine Wellness Centers Inc, increasing its footprint to 12 clinic locations across the US, in a $5 million cash-and-stock deal. Crain Communications is acquiring cannabis financial media site Green Market Report. The terms of the deal were not disclosed. Marijuana activists hold up a 51-foot inflatable joint during a rally at the U.S. Capitol to call on Congress pass cannabis reform legislation on Tuesday, Oct. 8, 2019. Photo by Caroline Brehman/CQ-Roll Call, Inc via Getty Images Policy movesThe House of Representatives on Thursday passed the SAFE Banking Act, a cannabis banking bill, as part of the National Defense Authorization Act. It's not clear whether the Senate will include cannabis reforms in its version of the defense package once the upper chamber takes it up. Italy is expected to hold a referendum on legalizing cannabis early next year after organizers gathered the 500,000 signatures within a week, reports Reuters. Research and dataA new report from the nonprofit Economic Policy Institute found that unionized cannabis workers could make $8,690 more per year than non-unionized peers. Psychedelics company Atai Life Sciences said on Tuesday that its platform company DemeRx has started its early-stage clinical trials of ibogaine to treat opioid use disorder.Cannabis data firm BDSA says in a report that cannabis sales will hit $31 billion this year, a 41% increase over last year. By 2026, BDSA expects cannabis sales to exceed $62 billion. EarningsMedMen reported its Q4 and FY21 results on Thursday. The company reported $42 million in revenue and a net loss of $46 million in Q4. For the full year, the company reported $145 million in revenue and a net loss of $157.6 million. What we're reading Why Amazon wants to make sure everyone knows it's totally cool with smoking pot now (Insider)Lawyers, race and money: Illinois' messy weed experiment (Politico)'Millions of pounds' of legal marijuana diverted to underground market, California lawsuit alleges (MJ Biz Daily)Getting high before exercise is the secret to sticking with a fitness routine, some athletes say (Insider)Illegal marijuana farms take West's water in 'blatant theft' (Associated Press)Marijuana banking sponsor discusses path through Senate after House approves reform for fifth time (Marijuana Moment)Read the original article on Business Insider.....»»

Category: topSource: businessinsiderSep 24th, 2021

Cathie Wood"s Ark Invest snapped up $55 million in Twitter stock after it rolled out its bitcoin-tipping feature

The Twitter bet reflects Wood's thinking that regulatory issues for digital assets will be manageable. Cathie Wood. Brendan McDermid/Reuters Cathie Wood's Ark Invest bought about 830,000 Twitter shares worth about $55 million on Thursday. She bought stock after the social-media company said it will let users send and get tips in bitcoin. The Twitter bet reflects Woods' thinking that regulatory issues for digital assets will be manageable. Sign up here for our daily newsletter, 10 Things Before the Opening Bell. Cathie Wood's Ark Invest bought about 830,000 Twitter shares worth $55 million Thursday after the social-a company rolled out a feature that enables users to send and receive tips in bitcoin.The investment firm's flagship fund ARK Innovation ETF purchased 661,141 shares in the company, while the ARK Next Generation Internet ETF picked up another 168,766 shares, according to a trade notification update.Cathie Wood's Twitter bet reflects her thinking that ongoing regulatory issues for digital assets will be manageable. Rule-enforcing agencies around the world have intensified their scrutiny of exchanges and cryptocurrencies as they have become more popular.In the US, Securities and Exchange Commission boss Chair Gary Gensler has taken a tough stance, saying recently that cryptocurrencies might not be a viable form of payment for long-term use. The SEC chairman has called for greater investor protection around the industry, stoking fears that Wall Street's top regulator is working overtime to create a set of rules that may limit innovation within the volatile cryptocurrency market.But Wood, whose investing strategy is centered around disruption innovation in tech, recently made a bullish prediction for bitcoin, saying it could hit as much as $500,000 in five years. The digital asset was trading at $42,563 Friday, 3.5% lower on the day, according to data from CoinDesk.Bitcoin tipping is not the only new feature Twitter flagged. The social network plans to allow its users to connect their crypto wallets to facilitate bitcoin tips, and to authenticate non-fungible tokens displayed on profiles as belonging to the account holder. There are no concrete plans for NFTs yet, but Twitter has said it's in the exploration process.Another new feature announced by Twitter is Super Follows, a monthly subscription service where creators charge a fee for access to premium content.Twitter was last trading at $66.72 per share on Friday, and is up 23% so far this year. Read More: Veteran professor Erik Gordon outlines why he doesn't expect a stock-market crash, calls Cathie Wood a dot-com 'throwback' for her grand claims, and warns against owning meme stocksRead the original article on Business Insider.....»»

Category: topSource: businessinsiderSep 24th, 2021

Futures Slide Alongside Cryptocurrencies Amid China Crackdown

Futures Slide Alongside Cryptocurrencies Amid China Crackdown US futures and European stocks fell amid ongoing nerves over the Evergrande default, while cryptocurrency-linked stocks tumbled after the Chinese central bank said such transactions are illegal. Sovereign bond yields fluctuated after an earlier selloff fueled by the prospect of tighter monetary policy. At 745am ET, S&P 500 e-minis were down 19.5 points, or 0.43%, Nasdaq 100 e-minis were down 88.75 points, or 0.58% and Dow e-minis were down 112 points, or 0.33%. In the biggest overnight news, Evergrande offshore creditors remain in limbo and still haven't received their coupon payment effectively starting the 30-day grace period, while also in China, the State Planner issued a notice on the crackdown of cryptocurrency mining, will strictly prohibit financing for new crypto mining projects and strengthen energy consumption controls of new crypto mining projects. Subsequently, the PBoC issued a notice to further prevent and dispose of the risks from speculating on cryptocurrencies, to strengthen monitoring of risks from crypto trading and such activities are illegal. The news sent the crypto space tumbling as much as 8% while cryptocurrency-exposed stocks slumped in U.S. premarket trading. Marathon Digital (MARA) drops 6.5%, Bit Digital (BTBT) declines 4.7%, Riot Blockchain (RIOT) -5.9%, Coinbase -2.8%. Big banks including JPMorgan, Citigroup, Morgan Stanley and Bank of America Corp slipped about 0.5%, while oil majors Exxon Mobil and Chevron Corp were down 0.4% and 0.3%, respectively, in premarket trading.Mega-cap FAAMG tech giants fell between 0.5% and 0.6%. Nike shed 4.6% after the sportswear maker cut its fiscal 2022 sales expectations and warned of delays during the holiday shopping season. Several analysts lowered their price targets on the maker of sports apparel and sneakers after the company cut its FY revenue growth guidance to mid-single- digits. Here are some of the biggest U.S. movers today: Helbiz (HLBZ) falls 10% after the micromobility company filed with the SEC for the sale of as many as 11m shares by stockholders. Focus Universal (FCUV), an online marketing company that’s been a favorite of retail traders, surged 26% in premarket trading after the stock was cited on Stocktwits in recent days. Vail Resorts (MTN) falls 2.7% in postmarket trading after its full-year forecasts for Ebitda and net income missed at the midpoint. GlycoMimetics (GLYC) jumps 15% postmarket after announcing that efficacy and safety data from a Phase 1/2 study of uproleselan in patients with acute myeloid leukemia were published in the journal Blood on Sept. 16. VTV Therapeutics (VTVT) surges 30% after company says its HPP737 psoriasis treatment showed favorable safety and tolerability profile in a multiple ascending dose study. Fears about a sooner-than-expected tapering amid signs of stalling U.S. economic growth and concerns over a spillover from China Evergrande’s default had rattled investors in September, putting the benchmark S&P 500 index on course to snap a seven-month winning streak. Elaine Stokes, a portfolio manager at Loomis Sayles & Co., told Bloomberg Television, adding that “what they did is tell us that they feel really good about the economy.” While the bond selloff vindicated Treasury bears who argue yields are too low to reflect fundamentals, others see limits to how high they can go. “We’d expected bond yields to go higher, given the macro situation where growth is still very strong,” Sylvia Sheng, global multi-asset strategist with JPMorgan Asset Management, said on Bloomberg Television. “But we do stress that is a modest view, because we think that upside to yields is still limited from here given that central banks including the Fed are still buying bonds.” Still, Wall Street’s main indexes rallied in the past two session and are set for small weekly gains. European equities dipped at the open but trade off worst levels, with the Euro Stoxx 50 sliding as much as 1.1% before climbing off the lows. France's CAC underperformed at the margin. Retail, financial services are the weakest performers. EQT AB, Europe’s biggest listed private equity firm, fell as much as 8.1% after Sweden’s financial watchdog opened an investigation into suspected market abuse. Here are some of the other biggest European movers today: SMCP shares surge as much as 9.9%, advancing for a 9th session in 10, amid continued hopes the financial troubles of its top shareholder will ultimately lead to a sale TeamViewer climbs much as 4.2% after Bankhaus Metzler initiated coverage with a buy rating, citing the company’s above-market growth AstraZeneca gains as much as 3.6% after its Lynparza drug met the primary endpoint in a prostate cancer trial Darktrace drops as much as 9.2%, paring the stock’s rally over the past few weeks, as a technical pattern triggered a sell signal Adidas and Puma fall as much as 4% and 2.9%, respectively, after U.S. rival Nike’s “large cut” to FY sales guidance, which Jefferies said would “likely hurt” shares of European peers Earlier in the session, Asian stocks rose for a second day, led by rallies in Japan and Taiwan, following U.S. peers higher amid optimism over the Federal Reserve’s bullish economic outlook and fading concerns over widespread contagion from Evergrande. Stocks were muted in China and Hong Kong. India’s S&P BSE Sensex topped the 60,000 level for the first time on Friday on optimism that speedier vaccinations will improve demand for businesses in Asia’s third-largest economy. The MSCI Asia Pacific Index gained as much as 0.7%, with TSMC and Sony the biggest boosts. That trimmed the regional benchmark’s loss for the week to about 1%. Japan’s Nikkei 225 climbed 2.1%, reopening after a holiday, pushing its advance for September to 7.7%, the best among major global gauges. The Asian regional benchmark pared its gain as Hong Kong stocks fell sharply in late afternoon trading amid continued uncertainty, with Evergrande giving no sign of making an interest payment that was due Thursday. Among key upcoming events is the leadership election for Japan’s ruling party next week, which will likely determine the country’s next prime minister. “Investor concerns over the Evergrande issue have retreated a bit for now,” said Hajime Sakai, chief fund manager at Mito Securities Co. in Tokyo. “But investors will have to keep downside risk in the corner of their minds.” Indian stocks rose, pushing the Sensex above 60,000 for the first time ever. Key gauges fell in Singapore, Malaysia and Australia, while the Thai market was closed for a holiday. Treasuries are higher as U.S. trading day begins after rebounding from weekly lows reached during Asia session, adding to Thursday’s losses. The 10-year yield was down 1bp at ~1.42%, just above the 100-DMA breached on Thursday for the first time in three months; it climbed to 1.449% during Asia session, highest since July 6, and remains 5.2bp higher on the week, its fifth straight weekly increase. Several Fed speakers are slated, first since Wednesday’s FOMC commentary set forth a possible taper timeline.  Bunds and gilts recover off cheapest levels, curves bear steepening. USTs bull steepen, richening 1.5bps from the 10y point out. Peripheral spreads are wider. BTP spreads widen 2-3bps to Bunds. In FX, the Bloomberg Dollar Spot Index climbed back from a one-week low as concern about possible contagion from Evergrande added to buying of the greenback based on the Federal Reserve tapering timeline signaled on Wednesday. NZD, AUD and CAD sit at the bottom of the G-10 scoreboard. ZAR and TRY are the weakest in EM FX. The pound fell after its rally on Thursday as investors looked ahead to BOE Governor Andrew Bailey’s sPeech next week about a possible interest-rate hike. Traders are betting that in a contest to raise borrowing costs first, the Bank of England will be the runaway winner over the Federal Reserve. The New Zealand and Aussie dollars led declines among Group-of-10 peers. The euro was trading flat, with a week full of events failing “to generate any clear directional move,” said ING analysts Francesco Pesole and Chris Turner. German IFO sentiment indeces will “provide extra indications about the area’s sentiment as  businesses faced a combination of delta variant concerns and lingering supply disruptions”. The Norwegian krone is the best performing currency among G10 peers this week, with Thursday’s announcement from the Norges Bank offering support In commodities, crude futures hold a narrow range up around best levels for the week. WTI stalls near $73.40, Brent near $77.50. Spot gold extends Asia’s gains, adding $12 on the session to trade near $1,755/oz. Base metals are mixed, LME nickel and aluminum drop ~1%, LME tin outperforms with a 2.8% rally. Bitcoin dips after the PBOC says all crypto-related transactions are illegal. Looking to the day ahead now, we’ll hear from Fed Chair Powell, Vice Chair Clarida and the Fed’s Mester, Bowman, George and Bostic, as well as the ECB’s Lane and Elderson, and the BoE’s Tenreyro. Finally, a summit of the Quad Leaders will be held at the White House, including President Biden, and the Prime Ministers of Australia, India and Japan. Market Snapshot S&P 500 futures down 0.3% to 4,423.50 STOXX Europe 600 down 0.7% to 464.18 German 10Y yield fell 8.5 bps to -0.236% Euro little changed at $1.1737 MXAP up 0.4% to 201.25 MXAPJ down 0.5% to 643.20 Nikkei up 2.1% to 30,248.81 Topix up 2.3% to 2,090.75 Hang Seng Index down 1.3% to 24,192.16 Shanghai Composite down 0.8% to 3,613.07 Sensex up 0.2% to 60,031.83 Australia S&P/ASX 200 down 0.4% to 7,342.60 Kospi little changed at 3,125.24 Brent Futures up 0.4% to $77.57/bbl Gold spot up 0.7% to $1,755.38 U.S. Dollar Index little changed at 93.14 Top Overnight News from Bloomberg China Evergrande Group’s unusual silence about a dollar-bond interest payment that was due Thursday has put a focus on what might happen during a 30-day grace period. The Reserve Bank of Australia’s inflation target is increasingly out of step with international counterparts and fails to account for structural changes in the country’s economy over the past 30 years, Westpac Banking Corp.’s Bill Evans said. With central banks from Washington to London this week signaling more alarm over faster inflation, the ultra-stimulative path of the euro zone and some of its neighbors appears lonelier than ever. China’s central bank continued to pump liquidity into the financial system on Friday as policy makers sought to avoid contagion stemming from China Evergrande Group spreading to domestic markets. A more detailed look at global markets courtesy of Newsquawk Asian equity markets traded mixed with the region failing to fully sustain the impetus from the positive performance across global counterparts after the silence from Evergrande and lack of coupon payments for its offshore bonds, stirred uncertainty for the company. ASX 200 (-0.4%) was negative as underperformance in mining names and real estate overshadowed the advances in tech and resilience in financials from the higher yield environment. Nikkei 225 (+2.1%) was the biggest gainer overnight as it played catch up to the prior day’s recovery on return from the Autumnal Equinox holiday in Japan and with exporters cheering the recent risk-conducive currency flows, while KOSPI (-0.1%) was lacklustre amid the record daily COVID-19 infections and after North Korea deemed that it was premature to declare that the Korean War was over. Hang Seng (-1.2%) and Shanghai Comp. (-0.8%) were indecisive after further liquidity efforts by the PBoC were offset by concerns surrounding Evergrande after the Co. failed to make coupon payments due yesterday for offshore bonds but has a 30-day grace period with the Co. remaining quiet on the issue. Finally, 10yr JGBs were lower on spillover selling from global counterparts including the declines in T-notes as the US 10yr yield breached 1.40% for the first time since early-July with the pressure in bonds also stemming from across the Atlantic following a more hawkish BoE, while the presence of the BoJ in the market today for over JPY 1.3tln of government bonds with 1yr-10yr maturities did very little to spur prices. Top Asian News Rivals for Prime Minister Battle on Social Media: Japan Election Asian Stocks Rise for Second Day, Led by Gains in Japan, Taiwan Hong Kong Stocks Still Wagged by Evergrande Tail Hong Kong’s Hang Seng Tech Index Extends Decline to More Than 2% European equities (Stoxx 600 -0.9%) are trading on the back foot in the final trading session of the week amid further advances in global bond yields and a mixed APAC handover. Overnight, saw gains for the Nikkei 225 of 2.1% with the index aided by favourable currency flows, whilst Chinese markets lagged (Shanghai Comp. -0.8%, Hang Seng -1.6%) with further liquidity efforts by the PBoC offset by concerns surrounding Evergrande after the Co. failed to make coupon payments due yesterday for offshore bonds. As context, despite the losses in Europe today, the Stoxx 600 is still higher by some 1.2% on the week. Stateside, futures are also on a softer footing with the ES down by 0.4% ahead of a busy Fed speaker schedule. Back to Europe, sectors are lower across the board with Retail and Personal & Household Goods lagging peers. The former has been hampered by losses in Adidas (-3.0%) following after hours earnings from Nike (-4.2% pre-market) which saw the Co. cut its revenue guidance amid supply chain woes. AstraZeneca (+2.1%) sits at the top of the FTSE 100 after announcing that the Lynparza PROpel trial met its primary endpoint. Daimler’s (+0.1%) Mercedes-Benz has announced that it will take a 33% stake in a battery cell manufacturing JV with Total and Stellantis. EQT (-6.5%) sits at the foot of the Stoxx 600 after the Swedish FSA announced it will open an investigation into the Co. Top European News EQT Investigated by Sweden’s FSA Over Suspected Market Abuse Gazprom Says Claims of Gas Under-supply to Europe Are ‘Absurd’ German Sept. Ifo Business Confidence 98.8; Est. 99 German Business Index at Five-Month Low in Pre-Election Verdict In FX, the rot seems to have stopped for the Buck in terms of its sharp and marked fall from grace amidst post-FOMC reflection and re-positioning in the financial markets on Thursday. Indeed, the Dollar index has regained some poise to hover above the 93.000 level having recoiled from 93.526 to 92.977 over the course of yesterday’s hectic session that saw the DXY register a marginal new w-t-d high and low at either end of the spectrum. Pre-weekend short covering and consolidation may be giving the Greenback a lift, while the risk backdrop is also less upbeat ahead of a raft of Fed speakers flanking US new home sales data. Elsewhere, the Euro remains relatively sidelined and contained against the Buck with little independent inspiration from the latest German Ifo survey as the business climate deteriorated broadly in line with consensus and current conditions were worse than forecast, but business expectations were better than anticipated. Hence, Eur/Usd is still stuck in a rut and only briefly/fractionally outside 1.1750-00 parameters for the entire week, thus far, as hefty option expiry interest continues to keep the headline pair in check. However, there is significantly less support or gravitational pull at the round number today compared to Thursday as ‘only’ 1.3 bn rolls off vs 4.1 bn, and any upside breach could be capped by 1.1 bn between 1.1765-85. CAD/NZD/AUD - Some payback for the non-US Dollars following their revival, with the Loonie waning from 1.2650+ peaks ahead of Canadian budget balances, though still underpinned by crude as WTI hovers around Usd 73.50/brl and not far from decent option expiries (from 1.2655-50 and 1.2625-30 in 1.4 bn each). Similarly, the Kiwi has faded after climbing to within single digits of 0.7100 in wake of NZ trade data overnight revealing a much wider deficit as exports slowed and imports rose, while the Aussie loses grip of the 0.7300 handle and skirts 1.1 bn option expiries at 0.7275. CHF/GBP/JPY - The Franc is fairly flat and restrained following a dovish SNB policy review that left in lagging somewhat yesterday, with Usd/Chf and Eur/Chf straddling 0.9250 and 1.0850 respectively, in contrast to Sterling that is paring some hawkish BoE momentum, as Cable retreats to retest bids circa 1.3700 and Eur/Gbp bounces from sub-0.8550. Elsewhere, the Yen has not been able to fend off further downside through 110.00 even though Japanese participants have returned to the fray after the Autumn Equinox holiday and reports suggest some COVID-19 restrictions may be lifted in 13 prefectures on a trial basis. SCANDI/EM/PM/CRYPTO - A slight change in the pecking order in Scandi-land as the Nok loses some post-Norges Bank hike impetus and the Sek unwinds a bit of its underperformance, but EM currencies are bearing the brunt of the aforementioned downturn in risk sentiment and firmer Usd, with the Zar hit harder than other as Gold is clings to Usd 1750/oz and Try down to deeper post-CBRT rate cut lows after mixed manufacturing sentiment and cap u readings. Meanwhile, Bitcoin is being shackled by the latest Chinese crackdown on mining and efforts to limit risks from what it describes as unlawful speculative crypto currency trading. In commodities, WTI and Brent are set the conclude the week in the green with gains in excess of 2% for WTI at the time of writing; in-spite of the pressure seen in the complex on Monday and the first-half of Tuesday, where a sub USD 69.50/bbl low was printed. Fresh newsflow has, once again, been limited for the complex and continues to focus on the gas situation. More broadly, no update as of yet on the Evergrande interest payment and by all accounts we appear to have entered the 30-day grace period for this and, assuming catalysts remain slim, updates on this will may well dictate the state-of-play. Schedule wise, the session ahead eyes significant amounts of central bank commentary but from a crude perspective the weekly Baker Hughes rig count will draw attention. On the weather front, Storm Sam has been upgraded to a Hurricane and is expected to rapidly intensify but currently remains someway into the mid-Atlantic. Moving to metals, LME copper is pivoting the unchanged mark after a mixed APAC lead while attention is on Glencore’s CSA copper mine, which it has received an offer for; the site in 2020 produced circa. 46k/T of copper which is typically exported to Asia smelters. Elsewhere, spot gold and silver are firmer but have been very contained and remain well-within overnight ranges thus far. Which sees the yellow metal holding just above the USD 1750/oz mark after a brief foray below the level after the US-close. US Event Calendar 10am: Aug. New Home Sales MoM, est. 1.0%, prior 1.0% 10am: Aug. New Home Sales, est. 715,000, prior 708,000 Central Bank Speakers 8:45am: Fed’s Mester Discusses the Economic Outlook 10am: Powell, Clarida and Bowman Host Fed Listens Event 10:05am: Fed’s George Discusses Economic Outlook 12pm: Fed’s Bostic Discusses Equitable Community Development DB's Jim Reid concludes the overnight wrap WFH today is a bonus as it’s time for the annual ritual at home where the latest, sleekest, shiniest iPhone model arrives in the post and i sheepishly try to justify to my wife when I get home why I need an incremental upgrade. This year to save me from the Spanish Inquisition I’m going to intercept the courier and keep quiet. Problem is that such speed at intercepting the delivery will be logistically challenging as I remain on crutches (5 weeks to go) and can’t grip properly with my left hand due to an ongoing trapped nerve. I’m very glad I’m not a racehorse. Although hopefully I can be put out to pasture in front of the Ryder Cup this weekend. The big news of the last 24 hours has been a galloping global yield rise worthy of the finest thoroughbred. A hawkish Fed meeting, with the dots increasing and the end of QE potentially accelerated, didn’t quite have the ability to move markets but the global dam finally broke yesterday with Norway being the highest profile developed country to raise rates this cycle (expected), but more importantly a Bank of England meeting that saw the market reappraise rate hikes. Looking at the specific moves, yields on 10yr Treasuries were up +13.0bps to 1.430% in their biggest daily increase since 25 February, as both higher real rates (+7.9bps) and inflation breakevens (+4.9bps) drove the advance. US 10yr yields had been trading in a c.10bp range for the last month before breaking out higher, though they have been trending higher since dropping as far as 1.17% back in early-August. US 30yr yields rose +13.2bps, which was the biggest one day move in long dated yields since March 17 2020, which was at the onset of the pandemic and just days after the Fed announced it would be starting the current round of QE. The large selloff in US bonds saw the yield curve steepen and the long-end give back roughly half of the FOMC flattening from the day before. The 5y30y curve steepened 3.4bps for a two day move of -3.3bps. However the 2y10y curve steepened +10.5bps, completely reversing the prior day’s flattening (-4.2bps) and leaving the spread at 116bp, the steepest level since first week of July. 10yr gilt yields saw nearly as strong a move (+10.8bps) with those on shorter-dated 2yr gilts (+10.7bps) hitting their highest level (0.386%) since the pandemic began.That came on the back of the BoE’s latest policy decision, which pointed in a hawkish direction, building on the comment in the August statement that “some modest tightening of monetary policy over the forecast period is likely to be necessary” by saying that “some developments during the intervening period appear to have strengthened that case”. The statement pointed out that the rise in gas prices since August represented an upside risks to their inflation projections from next April, and the MPC’s vote also saw 2 members (up from 1 in August) vote to dial back QE. See DB’s Sanjay Raja’s revised rate hike forecasts here. We now expect a 15bps hike in February. The generalised move saw yields in other European countries rise as well, with those on 10yr bunds (+6.6bps), OATs (+6.5bps) and BTPs (+5.7bps) all seeing big moves higher with 10yr bunds seeing their biggest climb since late-February and back to early-July levels as -0.258%. The yield rise didn’t stop equity indices recovering further from Monday’s rout, with the S&P 500 up +1.21% as the index marked its best performance in over 2 months, and its best 2-day performance since May. Despite the mood at the end of the weekend, the S&P now starts Friday in positive territory for the week. The rally yesterday was led by cyclicals for a second straight day with higher commodity prices driving outsized gains for energy (+3.41%) and materials (+1.39%) stocks, and the aforementioned higher yields causing banks (+3.37%) and diversified financials (+2.35%) to outperform. The reopening trade was the other main beneficiary as airlines rose +2.99% and consumer services, which include hotel and cruiseline companies, gained +1.92%. In Europe, the STOXX 600 (+0.93%) witnessed a similarly strong performance, with index led by banks (+2.16%). As a testament to the breadth of yesterday’s rally, the travel and leisure sector (+0.04%) was the worst performing sector on this side of the Atlantic even while registering a small gain and lagging its US counterparts. Before we get onto some of yesterday’s other events, it’s worth noting that this is actually the last EMR before the German election on Sunday, which has long been signposted as one of the more interesting macro events on the 2021 calendar, the results of which will play a key role in not just domestic, but also EU policy. And with Chancellor Merkel stepping down after four terms in office, this means that the country will soon be under new management irrespective of who forms a government afterwards. It’s been a volatile campaign in many respects, with Chancellor Merkel’s CDU/CSU, the Greens and the centre-left SPD all having been in the lead at various points over the last six months. But for the last month Politico’s Poll of Polls has shown the SPD consistently ahead, with their tracker currently putting them on 25%, ahead of the CDU/CSU on 22% and the Greens on 16%. However the latest poll from Forschungsgruppe Wahlen yesterday suggested a tighter race with the SPD at 25, the CDU/CSU at 23% and the Greens at 16.5%. If the actual results are in line with the recent averages, it would certainly mark a sea change in German politics, as it would be the first time that the SPD have won the popular vote since the 2002 election. Furthermore, it would be the CDU/CSU’s worst ever result, and mark the first time in post-war Germany that the two main parties have failed to win a majority of the vote between them, which mirrors the erosion of the traditional big parties in the rest of continental Europe. For the Greens, 15% would be their best ever score, and exceed the 9% they got back in 2017 that left them in 6th place, but it would also be a disappointment relative to their high hopes back in the spring, when they were briefly polling in the mid-20s after Annalena Baerbock was selected as their Chancellor candidate. In terms of when to expect results, the polls close at 17:00 London time, with initial exit polls released immediately afterwards. However, unlike the UK, where a new majority government can immediately come to power the day after the election, the use of proportional representation in Germany means that it could potentially be weeks or months before a new government is formed. Indeed, after the last election in September 2017, it wasn’t until March 2018 that the new grand coalition between the CDU/CSU and the SPD took office, after attempts to reach a “Jamaica” coalition between the CDU/CSU, the FDP and the Greens was unsuccessful. In the meantime, the existing government will act as a caretaker administration. On the policy implications, it will of course depend on what sort of government is actually formed, but our research colleagues in Frankfurt have produced a comprehensive slidepack (link here) running through what the different parties want across a range of policies, and what the likely coalitions would mean for Germany. They also put out another note yesterday (link here) where they point out that there’s still much to play for, with the SPD’s lead inside the margin of error and with an unusually high share of yet undecided voters. Moving on to Asia and markets are mostly higher with the Nikkei (+2.04%), CSI (+0.53%) and India’s Nifty (+0.52%) up while the Hang Seng (-0.03%), Shanghai Comp (-0.07%) and Kospi (-0.10%) have all made small moves lower. Meanwhile, the Evergrande group missed its dollar bond coupon payment yesterday and so far there has been no communication from the group on this. They have a 30-day grace period to make the payment before any event of default can be declared. This follows instructions from China’s Financial regulators yesterday in which they urged the group to take all measures possible to avoid a near-term default on dollar bonds while focusing on completing unfinished properties and repaying individual investors. Yields on Australia and New Zealand’s 10y sovereign bonds are up +14.5bps and +11.3bps respectively this morning after yesterday’s move from their western counterparts. Yields on 10y USTs are also up a further +1.1bps to 1.443%. Elsewhere, futures on the S&P 500 are up +0.04% while those on the Stoxx 50 are down -0.10%. In terms of overnight data, Japan’s August CPI printed at -0.4% yoy (vs. -0.3% yoy expected) while core was unchanged in line with expectations. We also received Japan’s flash PMIs with the services reading at 47.4 (vs. 42.9 last month) while the manufacturing reading came in at 51.2 (vs. 52.7 last month). In pandemic related news, Jiji reported that Japan is planning to conduct trials of easing Covid restrictions, with 13 prefectures indicating they’d like to participate. This is likely contributing to the outperformance of the Nikkei this morning. Back to yesterday now, and one of the main highlights came from the flash PMIs, which showed a continued deceleration in growth momentum across Europe and the US, and also underwhelmed relative to expectations. Running through the headline numbers, the Euro Area composite PMI fell to 56.1 (vs. 58.5 expected), which is the lowest figure since April, as both the manufacturing (58.7 vs 60.3 expected) and services (56.3 vs. 58.5 expected) came in beneath expectations. Over in the US, the composite PMI fell to 54.5 in its 4th consecutive decline, as the index hit its lowest level in a year, while the UK’s composite PMI at 54.1 (vs. 54.6 expected) was the lowest since February when the country was still in a nationwide lockdown. Risk assets seemed unperturbed by the readings, and commodities actually took another leg higher as they rebounded from their losses at the start of the week. The Bloomberg Commodity Spot index rose +1.12% as Brent crude oil (+1.39%) closed at $77.25/bbl, which marked its highest closing level since late 2018, while WTI (+1.07%) rose to $73.30/bbl, so still a bit beneath its recent peak in July. However that is a decent rebound of roughly $11/bbl since its recent low just over a month ago. Elsewhere, gold (-1.44%) took a knock amidst the sharp move higher in yields, while European natural gas prices subsidised for a third day running, with futures now down -8.5% from their intraday peak on Tuesday, although they’re still up by +71.3% since the start of August. US negotiations regarding the upcoming funding bill and raising the debt ceiling are ongoing, with House Speaker Pelosi saying that the former, also called a continuing resolution, will pass “both houses by September 30,” and fund the government through the first part of the fiscal year, starting October 1. Treasury Secretary Yellen has said the US will likely breach the debt ceiling sometime in the next month if Congress does not increase the level, and because Republicans are unwilling to vote to raise the ceiling, Democrats will have to use the once-a-fiscal-year tool of budget reconciliation to do so. However Democrats, are also using that process for the $3.5 trillion dollar economic plan that makes up the bulk of the Biden agenda, and have not been able to get full party support yet. During a joint press conference with Speaker Pelosi, Senate Majority Leader Schumer said that Democrats have a “framework” to pay for the Biden Economic agenda, which would imply that the broad outline of a deal was reached between the House, Senate and the White House. However, no specifics were mentioned yesterday. With Democrats looking to vote on the bipartisan infrastructure bill early next week, negotiations today and this weekend on the potential reconciliation package will be vital. Looking at yesterday’s other data, the weekly initial jobless claims from the US for the week through September 18 unexpectedly rose to 351k (vs. 320k expected), which is the second week running they’ve come in above expectations. Separately, the Chicago Fed’s national activity index fell to 0.29 in August (vs. 0.50 expected), and the Kansas City Fed’s manufacturing activity index also fell more than expected to 22 in September (vs. 25 expected). To the day ahead now, and data highlights include the Ifo’s business climate indicator from Germany for September, along with Italian consumer confidence for September and US new home sales for August. From central banks, we’ll hear from Fed Chair Powell, Vice Chair Clarida and the Fed’s Mester, Bowman, George and Bostic, as well as the ECB’s Lane and Elderson, and the BoE’s Tenreyro. Finally, a summit of the Quad Leaders will be held at the White House, including President Biden, and the Prime Ministers of Australia, India and Japan. Tyler Durden Fri, 09/24/2021 - 08:12.....»»

Category: blogSource: zerohedgeSep 24th, 2021